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.Abstract.
!
PTPN22!encodes!the!protein!tyrosine!phosphatase!Lyp.!Lyp!is!a!known!negative!regulator!of!TCR!
signalling!where!it!has!been!shown!to!dephosphorylate!Src!family!kinases.!Certain!mutations!in!
PTPN22!are!associated!with!increased!risk!of!autoimmune!disease!such!as!rheumatoid!arthritis.!This!
includes!the!well!documented!C1858T!substitution.!Previous!studies!into!understanding!the!role!of!
PTPN22!in!health!and!disease!have!focused!on!lymphocytes,!primarily!T!cells.!Despite!this,!myeloid!
cells!have!a!higher!expression!of!Lyp.!Lyp!can!also!interact!with!other!signalling!proteins,!including!
the!Rho!GTPase,!Vav,!which!has!multiple!roles!in!cell!signalling!pathways.!This!project!therefore!
looked!at!the!role!of!Lyp!in!primary!human!macrophages!by!using!a!competitive!reversible!inhibitor!
of!Lyp!protein!activity.!It!was!shown!that!Lyp!is!a!negative!regulator!of!reactive!oxygen!species!(ROS)!
production!in!unstimulated!cells!and!in!response!to!PMA.!We!also!show!that!primary!macrophages!
heterozygous!for!the!autoimmuneRassociated!C1858T!variant!produce!high!levels!of!proR
inflammatory!cytokines!in!apparently!unstimulated!conditions.!These!novel!findings!provide!insight!
into!how!C1858T!is!associated!with!inflammatory!disease!such!as!rheumatoid!arthritis.!!
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Abbreviations 
 
 
 
BCR B cell receptor 
DAG Diamino glycerol 
ERK Extracellular-signal-regulated kinases 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
IP3 Inositol triphosphate 
ITAM Immunoreceptor tyrosine-based activation motiff 
LAT Linker for activation of T cells 
MAPK Mitogen activated protein kinase 
MHC Major histocompatibility complex 
NADPH Nicotinamide adenine dinucleotide phosphate 
PI3K phosphoinositide 3-kinase 
PKC protein kinase C 
PLCγ phospholipase  C  γ 
SH2 Src homology 2 
SH3 Src homology 3 
SNP single nucleotide polymorphism 
TCR T cell receptor 
WASP Wiskott-Aldrich syndrome protein 
ZAP-70 zeta chain associated protein kinase 70 
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Introduction 
 
Many autoimmune diseases, including rheumatoid arthritis are thought to have genetic 
predispositions and many genome-wide association studies have identified genetic loci which 
correlate with autoimmunity. A large number of genes may be involved in susceptibility to particular 
diseases with, for example, at least 46 contributing to the population risk of developing rheumatoid 
arthritis 1. 
Many of the strongest associations are among the MHC loci 2 but the strongest susceptibility loci 
outside the MHC 3-7 is a single-nucleotide-polymorphism (SNP) within PTPN22. PTPN22 encodes Lyp 
phosphatase, which is a known negative regulator of TCR signalling and so studies into Lyp and 
autoimmunity have concentrated on lymphocytes. This is despite reports that Lyp expression is 
actually relatively low within T cells and high within myeloid cells 8. Myeloid cells, particularly 
macrophages are the predominant cell type within the inflamed synovium in rheumatoid arthritis 
(RA) 9.  
For this reason it would be of interest to investigate the possible roles of Lyp in macrophages. In 
order to do this, we must first understand the role of Lyp in T cells, as discussed below. 
Lyp phosphatase 
Lyp, encoded by PTPN22, is a protein tyrosine kinase which is a member of the PEST non-receptor 
classical class I protein tyrosine phosphatase (PTP) family 10. Structurally, Lyp contains an N-terminal 
PTP domain and a non-catalytic C-terminal domain. Within the C-terminal are four proline-rich 
motifs followed by a C-terminal homology domain. PEP, the murine homolog shares 89% amino acid 
identity within the PTP domain and 61% within the non-catalytic regions 10. Lyp and PEP are 
expressed in cells of the haematopoietic system 10,11 with  both  of  these  PTP’s  having been implicated 
in negative regulation of TCR signalling 10,12,13. Lyp phosphatase came to prominence after an SNP 
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variant was found be linked to the autoimmune disease type-1 diabetes 3. This variant arises from a 
C1858T base substitution, resulting in an R620W amino acid change. The same R620W variant has 
since been identified as a risk factor in RA 4,5 and systemic lupus erythematous 6,7. 
The pathways involved in TCR signalling have been reviewed elsewhere 14 and are summarised in 
figure 1. In brief, upon TCR ligation, Src family kinases such as Lck and Fyn are recruited to the TCR 
complex. Src family kinases are capable of intracellular phosphorylation of ITAMs found on CD3 and 
the  ζ chains within the TCR complex. Zap-70, a Syk kinases family member, is recruited to double 
phosphorylated ITAMs via its two SH2 domains. Lck can then phosphorylate Zap70 within its 
activation tyrosines Y319 and Y343.  
Adaptor proteins are essential in linking the early signalling events with downstream molecules. LAT 
is a membrane bound adaptor recruited to the TCR complex. Zap-70 can phosphorylate LAT at 
several tyrosines. LAT can then recruit multiple further molecules via their SH2 domains including 
PLCγ,  PI3K,  SLP76  and  Grb2. This allows formation of signalling microclusters where localised 
protein-protein interactions occur. These molecules are important in the downstream signalling 
pathways typical of T cell activation. Lck associates with CD8 and CD4 co-receptors. Under steady 
state, Lck is phosphorylated at the negative regulatory tyrosine Y505 by Csk, keeping it inactive 15,16. 
Phosphorylated Y505 causes the inhibitory ‘tail  bite’  effect  where  Lck’s  internal  SH2  domain  binds  to 
Y505 16. Under steady state, Csk associates through its SH2 domain with phosphorylated PAG at the 
plasma membrane, where it can negatively regulate Lck 17. Lck is also a substrate of Lyp 12. It is 
believed Lyp keeps the activation tyrosine Y394 dephosphorylated, thereby contributing to Lck 
inactivation 17.  
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Figure 1: Summary of CD4 T cell TCR signalling and Lyp interaction. After antigen stimulation of the TCR, the CD4 co-
receptor comes into proximity, bringing with it Lck. Lck phosphorylates the ITAMs of the CD3 chains and zeta chains 
associated with the TCR. Zap70 is recruited to the ITAMs and phosphorylated and activated by Lck. Zap70 can then 
phosphorylate LAT and the several molecules that it recruits, forming a signalling complex. PLCγ can cleave membrane 
bound phosphoinositol biphsophate (not showing), generating IP3 and DAG. IP3 acts as a secondary messenger 
facilitating calcium flux. DAG can activate isoforms of PKC without calcium, and isoforms with calcium. The MAPK’s  ERK,  
JNK and P38 are important in many cell signalling cascades and processes. TCR, T cell receptor; PLCγ, phospholipase C 
gamma; DAG, diacylglycerol; LAT, linker for activation of T cells; SOS, son of sevenless; P13K, phosphoinositide 3 kinase; 
IP3, inositol triphosphate; PKC, phosphokinase C; ZAP-70, zeta chain associated protein kinase 70; NFκB, nuclear factor 
Κb. 
 
Furthermore, Lyp/PEP can interact with Csk 13,18,19. This interaction is mediated through the Csk SH3 
domain and the Proline-rich 1 (P1) domain of Lyp. One model proposes this interaction to be 
essential for Lyp function 17. While Csk is bound to PAG, its recruitment of Lyp to the lipid raft would 
bring it into the proximity of its substrates, allowing a synergistic inhibition of Lck under steady-state 
conditions. Upon TCR stimulation, Lck can be activated and PAG is dephosphorylated by an unknown 
phosphatase. Csk can then no longer bind and is released 20. Lck is then dephosphorylated at Y505 by 
an unknown phosphatase. This is followed by Lck autophosphorylation at Y394 and its full activation.  
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The R620W mutation and the role of Lyp in T cells  
The R620W mutation occurs within the P1 domain motif, the site of the Csk interaction. It is 
proposed this mutation prevents Lyp from binding Csk 3. A cell line transfection study with the W620 
variant suggested it to cause a loss of phosphatase function 21. The variant could also be a less stable 
protein 22. The PEP variant R619W compares to the Lyp R620W mutation. When knocked into mice, 
PEP protein levels were largely reduced. The authors argue that a reduced Lyp protein availability 
results in a reduced TCR negative regulation causing increased T cell activation.  Supporting this, 
knock-in mice had increased activated/memory lymphocytes. Yet mice did not exhibit signs of 
autoimmunity despite the well identified correlation between Lyp and autoimmunity. It should also 
be noted PEP and Lyp are much less conserved within the catalytic domain, so it is possible that 
protein interactions and any mechanisms of degradation could differ. 
Multiple other studies have found the variant to have a gain of phosphatase function. Primary T cells 
homozygous and heterozygous for W620 or transfection of primary human T cells with the variant 
have been found to have greater inhibition of TCR signalling. This includes reductions in calcium flux; 
phosphorylation of ITAMS, ERK and LAT; IL2 and IL10 production; activation markers; and 
proliferation 23 24 25.  
The general consensus from these results is that the R620W mutation results in a gain of function; 
i.e. increased inhibition of TCR signalling. There is some difficulty in understanding how this concept 
fits into the model of Lyp and TCR signalling. It may be that the poor interaction with Csk actually 
impedes Lyp negative regulation. Lck is capable of phosphorylating Lyp at inhibitory tyrosine Y536 26. 
Phosphorylation here is important in TCR negative regulation. The W620 variant shows less 
phosphorylation here and it’s proposed a Csk interaction is required to allow Lck to act on Lyp. Lyp 
can also be negatively phosphorylated by PKCδ at serine 35 27. It is possible that failure to interact 
with Csk could also impede this negative regulation. 
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Evidence has accumulated against the requirement for Lyp/Csk interaction at the plasma membrane 
for Lyp function. When Csk is bound to PAG, it was found not to co-immunoprecipitate with Lyp or 
PEP 25,28. Vang and colleagues provide evidence for a model where Lyp and Csk are in a cytosolic 
complex within resting T cells, with Lyp in an inhibited state. Upon TCR ligation, the complex 
dissociates and Lyp can be recruited to the lipid raft. Here Lyp can function as a phosphatase and 
negatively regulate T cell signalling.25. So Lyp could function in negative feedback of TCR stimulation. 
No matter which model is correct, it is still not fully understood how a gain in Lyp phosphatase 
function could relate to an increased risk in autoimmunity. One theory arose from the SKG mouse 
strain 22. These mice spontaneously develop a chronic arthritis similar to RA. This is due to a ZAP-70 
mutation causing poor association with ITAMs, therefore reducing its phosphorylative capacity. This 
results in poor signal transduction upon TCR ligation. An altered thymocyte selection was found in 
SKG mice, due to the lowered TCR signalling threshold in autoreactive thymocytes that would 
otherwise have been deleted. The concept of an increased positive selection of autoreactive 
thymocytes due to an increased negative regulation by Lyp variants is therefore possible.  
As mentioned above Lyp has a number of target substrates among proteins involved in TCR 
signalling, but it has a broader range of substrates than these, as observed from substrate trapping 
experiments with a Lyp variant without phosphatase activity. In these experiments Lyp has also been 
found to associate with Vav proteins 12. These have a wide range of functions in activation and 
adhesion of leukocytes and the roles of Vav are discussed below. 
Vav 
The Vav family of proteins are a conserved group found from nematodes to humans where they act 
as guanine exchange factors (GEFs) for Rho GTPases 29.  Rho GTPases are molecular switches which 
are either in the  ‘active’  GTP-bound or  ‘inactive’  GDP-bound form. Vav proteins catalyse the 
activation of the Rho GTPase via exchange of GDP to GTP. In this active state, Rho GTPases can 
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interact with effectors, playing essential roles in the regulation of actin polymerisation; cell cycle; 
gene expression; and cell adhesion 30. Vav1, Vav2 and Vav3 are all found in mammals, where Vav1 is 
restricted mainly to haematopoietic cells while Vav2 and Vav3 have a much broader expression 29.   
Vav Structure 
Vav protiens are highly conserved with the same basic structure. The central Dbl homology (DH) 
domain exhibits GEF activity to Rho GTPases. To the carboxyl side lie the pleckstrin homology (PH) 
and C1 domains which have been implicated with the regulation of GEF activity. Amino to DH is the 
calponin homology (CH) and the acidic domains which can inhibit GEF activity. Also found at the 
carboxyl terminus are the two SH3 and single SH2 domains. SH3 and SH2 domains function in 
protein-protein interactions and therefore it is believed that Vav can also function as an adaptor 
during signalling, a function not found in other GEFs 31.  
Vav Activation 
Vav GEF activity depends on Tyrosine phosphorylation 32. Upon TCR and BCR stimulation, Vav is 
rapidly phosphorylated 33,34 by Src family kinases 31.  Phosphorylation of the three Tyrosine residues 
within the acidic domain allows binding of GTPase substrates 35. Phosphorylation within the carboxyl 
terminal can also regulate GEF activity 36. Phosphoinisitols which bind the PH domain can also 
regulate GEF activity and assist in Vav membrane recruitment 37. Vav1 has been shown to favour its 
GEF activity towards Rac1, Rac2 and RhoG 32,38. Vav2 and Vav3 favour RhoA, RhoB and RhoG 39,40.  
Vav functions 
Since Vav is activated following surface receptor stimulation, Vav proteins may act as links between 
the cell surface receptor and signal transduction, particularly cytoskeletal rearrangements. For 
example, in TCR signalling and the immunological synapses 41; macrophage adhesion 42; neutrophil 
activation after integrin 43; and neutrophil and macrophage chemotaxis to receptor ligands  44 45.  
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Interestingly, Vav also plays an important role in other cellular activities as best exemplified in TCR 
signalling. T cells lacking Vav1 show defects in proliferation, reduced activation marker expression, 
reduced calcium flux and cytokine release after TCR stimulation 31.  Furthermore, Vav1 deficient 
mice have defects in positive and negative selection of thymocytes 31. The functions of Vav1 in T cell 
signalling are discussed below.  
Vav1 GEF activity is required in some T cell signalling pathways involving Rac, Akt and integrins. 
However GEF activity is not required in calcium flux, ERK MAP kinase activation, cell polarisation and 
NFAT activation 36,46. The SH3-SH2-SH3 cassette and acidic domain tyrosines can interact with several 
proteins involved in TCR signalling such as Shc, Csk, Sap, NCK, SLP76, ZAP-70 Grb2 31,36 and Lck, PI3K 
and  PLCγ1  47. Together, this indicates Vav to have adaptor functions. 
Vav complex formation can lead to many downstream effector functions, including PLCγ1 activation 
48. A Vav1/SLP76 complex can recruit and activate PLCγ1  48,49, essential in several downstream 
functions, including calcium flux, proliferation, NFAT activation, and ERK activation 50-52. Vav can lead 
to Ras GEF activation through several mechanisms, including cytoskeletal rearrangements 53 and 
Grb2 recruitment, which recruits the Ras GEF SOS 54. The same SH3 domain allows a 
Vav1/NCK/SLP76 complex, which controls actin rearrangement at the immunological synapse 
through WASP  55,56. 
Therefore, Vav has several roles in T cell signalling and activation and Lyp could potentially regulate 
these activities through Vav by directly dephosphorylating essential Tyrosine residues. Since Lyp is 
expressed highest within myeloid cells such as macrophages it’s important to understand these 
pathways. 
Macrophage FcγR  signalling 
Fcγ  receptors (FcγR)  bind to the Fc portion of IgG antibodies. There are three FcγR  classes  in  humans:  
RI (CD64) which binds with high affinity to IgG; RII (CD32) and RIII (CD16) which bind with low affinity 
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to IgG 57. Each of these receptors express or are associated with an intracellular signalling domain. 
The  inhibitory  receptor,  (only  FcγRIIb)  contains  an  ITIM  and  can  have  negative  effects  on  cell  
activation. The activating receptors contain/associate with an ITAM and can facilitate cell activation 
signals and phagocytosis. FcγRs  belong  to  the  same  immunoglobulin  superfamily as the TCR. 
Therefore, both signalling pathways have considerable overlap.   
FcγR	  Initiation of signalling 
ITAM phosphorylation is carried out by the Src family kinases Lyn, Hck and Fgr and Syk kinase is 
recruited and phosphorylated  58-60 61,62. Syk and Lyn can phosphorylate LAT, allowing downstream 
signalisomes 63,64. Despite SLP76 being highly expressed in macrophages, it appears not to be 
required in signal transduction 65-67.  
The downstream pathways 
Just like TCR signalling, there is downstream activation of PLCγ, PI3K, MAPKs and transcription 
factors 60. Details of some of these pathways are described below. 
As  seen  in  TCR  signalling,  PLCγ  can  be  recruited  to  LAT  and  activated  by  Syk  kinase  activity,  resulting  
in IP3 generation and subsequent calcium release  68 69. This calcium flux may not be required for 
FcγR-mediated phagocytosis 70,71 but is required for phagosomal maturation 72. During  FcγR-
mediated  phagocytosis,  PLCγ  is  recruited  to  the  phagocytic  cup. Its inhibition results in poor 
phagocytosis in murine macrophages 73. Since calcium may not be required initially,  the  PLCγ  
generation of DAG may be important here. DAG is capable of activating the novel and classic PKC 
isoforms which have a role in ERK activation in macrophage phagocytosis 
After FcγR stimulation, PKC can activate Raf-1 which can initiate the ERK MAPK pathway. Inhibition 
of ERK can also impair phagocytosis in macrophages 74,75. 76.  ERK’s  role  here  could  possibly  be  the  
activation of PLA2 which mediates production of Arachidonic acid which facilitates FcγR-mediated 
phagocytosis 77. PI3K is recruited to LAT where it is activated by Syk 57. Inhibition of PI3K can prevent 
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FcγR-mediated phagocytosis due to a failure of phagosome closure in murine macrophages 78,79 80. 
PI3K can also initiate ERK activation after FcγR  ligation  in  monocytes  and  macrophages  81,82.  
In macrophages, the rho family GTPases Rac and cdc42 are essential in actin polymerisation and 
ingestion of IgG opsonised substrates 83,84. Vav is required in FcγR-mediated phagocytosis in murine 
macrophage-like cell lines85 but not in murine primary macrophages 86. Similarly, FcγR-mediated Rac 
activation did not require Vav in these primary macrophages 86  
Macrophage ROS production 
ROS production requires the NADPH oxidase modular enzyme. The classical model of NADPH oxidase 
activation involves a calcium-dependent activation of PKC 87. PKC then phosphorylates NADPH 
subunits within the cytosol. A complex of p47phox/p67phox/p40phox with Rac1 or Rac2 then forms. 
Vav is required for Rac activation. This complex translocates to the plasma membrane where it 
assembles with the flavocytochromes gp91phox and p22phox forming the full enzyme. The oxidase 
is then active within the membrane of phagosomes. NADPH is utilised as a substrate to reduce O2 to 
O2-, initiating ROS production.  
ROS production accompanies many macrophage downstream signalling events. For example, FcγR-
mediated phagocytosis and production of ROS are mediated by related pathways in macrophages. 
Here, the Syk, PI3K, PKC activation pathway leads to both phagocytosis and ROS production after 
FcγR  ligation 76.  
Macrophage Cytokine signalling 
Macrophages are major producers of pro-inflammatory cytokines during inflammation, including 
macrophages in the synovium during RA. The regulation of these cytokines depends on transcription 
factors that are typically activated in several receptor signal transduction pathways. NFκB is an 
obvious example 88 and this has been shown in macrophage TNFα  regulation 89,90. MAPKs are also 
implicated in the regulation of TNFα. P38 MAPK can regulate  TNFα  mRNA stability 91 and regulate 
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several transcription  factors,  including  NFκB  92-94. In primary human macrophages, p38 MAPK has 
been  shown  to  regulate  TNFα  transcription  via  NFκB  91. Another study described p38 MAPK 
regulation of NFκB  in  conjunction with ERK 95. 
NFAT is another important transcription factor in cytokine regulation, including TNFα 96. Most of the 
NFAT family are activated through calcium signalling. NFAT acts synergistically with AP-1. AP-1 
activation depends on heavily on MAPK pathways 97. Therefore, multiple points where Lyp and Vav 
could influence cytokine production exist. 
This project 
The aim of this project is to investigate whether Lyp is involved in the three major macrophage 
signalling pathways discussed: FcγR; ROS production; and cytokine production. We believe that 
based the molecules involved in these pathways, Lyp is likely to be involved, either directly, or 
through Vav regulation. The use of a Lyp inhibitor will be used to investigate the effect found within 
these pathways. We hypothesized that Lyp inhibition will cause decreased negative regulation of 
these pathways, in other words, these pathways will be more active. By using a gold-based 
compound capable of competitive reversible inhibition of PTP activity, with a 10-fold selectivity for 
Lyp  over  other  PTP’s 98 we showed that Lyp is involved in Macrophage signalling. This was most 
evident In ROS production. We also show that Lyp might regulate Vav phosphorylation. 
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Materials and Methods 
Primary macrophage generation from human blood  
From healthy donor from the lab 
300μl of EDTA (Sigma) per 10ml of blood was added to a 50ml tube. 30 to 40mls of blood was then 
drawn and poured into the tube. Blood was made up to 50ml with RPMI (Sigma). 15ml of ficoll (GE 
healthcare) was added each to two 50ml tubes. 25ml of blood were then pipetted on top of the ficoll 
layers. These tubes were centrifuged for 30mins at 1500RPM with no brake. The PBMC layer was 
removed and added to separate tubes. These tubes were topped up to 50ml with RPMI then 
centrifuged for 10mins at 1500RPM. Supernatant was aspirated, cells resuspended in RPMI and 
counted. 
Cells were then centrifuged at 300g for 10mins. Supernatant was aspirated then cells resuspended in 
80μl of macs buffer (PBS (Oxoid); 0.5% BSA (Sigma); 2mM EDTA) per 10x107 cells. CD14 microbeads 
(Militenyl Biotech) were then used to positively select CD14 expressing PBMCs using a MACs 
separator according to manufacturer’s instructions. Selected cells were resuspended in RPMI and 
counted. Cells were then washed in RPMI. 
From blood apheresis cone 
Blood  was  made  up  to  50ml  with  RPMI.  PBMCs  were  purified  as  above.  PBMC’s  were  washed  with  
HBSS media (Sigma) at 1400RPM for 5 minutes at 20°C three times. Cells resuspended in 40ml of 
RPMI with 10% fetal calf serum (fcs) (Sigma). 20mls of cell suspension was layered on top of a 15ml 
Percoll solution (GE healthcare). This was then centrifuged at 500g with acceleration and 
deceleration set low at 1 for 30minutes at 20°C. The middle monolayer of cells was extracted and 
made up to 50ml with RPMI, then centrifuged at 1800RPM for 5 minutes.  
Cells were resuspended to 4x106 per ml in RPMI. 5mls of cells were plated onto petri dishes and 
incubated for 1 hour at 37°C to allow monocytes to adhere. RPMI was thrown off, 5mls of media 
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(RPMI; 10% fcs; Glutamine, streptavidin, penicillin (Sigma)) was then added and cells were scraped 
off the plate. Media with scraped cells was transferred to a fresh tube and centrifuged for 10 
minutes at 1500RPM.  
Macrophage differentiation  
Cells were resuspended to 1x106/ml in media. GM-CSF (Invitrogen) was added at 1μl/ml of 
suspension. Cells were plated in 6 well plates at 2x106/well. Plates were incubated at 37°C for six 
days. 
Macrophage removal  
Adherent macrophages had to be removed from the bottom of plate wells. Medium was taken off 
and added to a 15ml tube. 0.5ml of Hanks enzyme-free cell dissociation buffer (Gibco) was added to 
each well. Plates were incubated for 15minutes at 37°C. Plates were then vigorously tapped to help 
removal. A cell scraper was then used to scrape of remaining cells. Solution was then added to the 
falcan tube. The tube was centrifuged for 10minutes at 15000RPM. Cells were washed in fresh 
media twice. 
Western blot 
Preparation of samples: 
5x106 cells per treatment were removed from media. Cells were washed in media and then 
resuspended to 5x106 cells per ml of media. 5x106 cells were then incubated with PTP Lyp inhibitor 98 
(Calbiochem) at a final concentration of 0.6 or 1.25μM  and  5x106  control cells incubated without Lyp 
inhibitor for 40 minutes at 37°C. Cells were then washed in PBS before resuspension in 500ml of PBS 
and transferring to eppendorfs. Cells were washed twice in PBS at 3000RPM for 5 minutes before 
resuspension  in  40μl  of  PBS.  10μl  of  5x  SDS  loading  buffer  was  then  added  to  cells 
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Sample running and membrane transfer: 
SDS containing samples were heated on a 100°C heating block for 10 minutes. 10ul of sample was 
then pipetted into the appropriate well. 10ul of prestained marker loading control (Invitrogen) was 
then added. The gel was then run until proteins reached the bottom of the gel. Proteins on gel were 
transferred onto membrane using the turbo where the membrane is soaked in methanol for one 
minute; gel placed on the membrane, with seven pieces of filter paper on top and bottom. 
Sample development: 
For antibodies used, see tables 1 and 2. Membrane was blocked in 5% BSA in PBSTT (PBS; 0.1% 
Tween (Fischer Scientific) for one hour on a shaker at room temperature (RT). 10ml of primary 
antibody solution in 5% BSA in PBSTT was added then membrane was left overnight at 4°C on a 
shaker. Membrane was washed for 10 minutes on a shaker at RT in PBSTT three times. 10ml of 
secondary antibody solution in PBSTT was added. Membrane was left on a shaker for one hour at RT.  
Membrane was washed for 10 minutes on as shaker at RT in PBSTT three times. Membrane was 
developed in ECL solution A and B (GE healthcare) for 3 minutes. Membrane was then run on a 
chemidoc. 
Table 1: western blot primary antibody  
Antibody  Dilution Company 
Rabbit anti-human Vav   1/1000 Milipore 
Rabbit anti-human Phospho-
Vav  
1/1000 Santa Cruz Biotech 
 
Mouse anti-phospho-Tyrosine  1/1000 Milipore 
 
Table 2: western blot secondary antibody 
Antibody  Conjugation Dilution Company 
Goat anti-mouse  HRP 1/10000 GE healthcare 
Donkey anti-rabbit  HRP 1/10000 GE healthcare 
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FACs DHR 
Cells were resuspended in fresh media at 1x106 cells per ml. Cells were treated with and without Lyp 
inhibitor at 1x106 cells per treatment group. 200μl of cells from each Lyp inhibitor concentration and 
control cells were added to FACS tubes. For each concentration, one tube is left without dye. For the 
rest of tubes, 4μl of Dihydrorhodamine 1,2,3 (DHR) solution (invitrogen) was added to give a final 
concentration of 10μM. Each tube is then incubated for 5 minutes at 37°C. One tube from each 
concentration then has the appropriate agonist added: LPS at 10ng/ml or PMA at 200nM (both 
Sigma). One tube from each concentration is left untreated. 200μl of PBS was then added to each 
tube. Tubes were run and fluorescence measured using FL1 of a Dako Cyan ADP flow cytometer. 
Summit v4.3 was used to analyse the data.  
Calcium signalling 
Cells were resuspended in fresh media at 1x106 cells per ml. 1.5x106 cells were required for each 
treatment group, Lyp inhibitor was added to give desired concentrations. To prepare the dye, 110μl 
of DMSO (Sigma) was added to a fresh tube of Indo-1 AM (Invitrogen). Dye was added to cells at 7μl 
per ml of cell suspension. Cells were then incubated at 37°C for 40 minutes. Indo-1 AM passively 
diffuses into cells. Cellular esterases cleave this leaving the cell impermeant calcium indicator Indo-
1. The binding of Indo-1 to calcium causes a shift in fluorescence emission. The ratio of bound to 
unbound fluorescence is then used to indicate intracellular free calcium levels. 
Cells were then centrifuged for 10minutes at 15000RPM at 20°C and supernatant flicked off. Cells 
then washed twice in HBSS. Cells were then resuspended in HBSS (Gibco) to 1x106 cells per ml with 
1.5ml of cell suspension added to the appropriate cuvette.  
Each cuvette was placed in a 37°C water bath for 5 minutes before running in the fluorometer 
machine with a magnetic stirrer. Agonists were added at appropriate times. Agonists added were 8μl 
of primary mouse anti-human CD64 (Serotec) followed by 16 μl goat anti-mouse (Sigma) to cause 
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crosslinkage. 5μl Ionomycin (Sigma) was added once calcium levels were basal as a positive loading 
control. 
Cytokine ELISA 
For each donor, macrophages were differentiated as before, but in a 96 well plate, with 2.5x104 cells 
per well. After 6 days differentiation, lipopolysaccharide (LPS) was added added to appropriate wells 
at a concentration of 10ng/ml. Lyp inhibitor was also added to appropriate wells to give a final 
concentration of 1μM.  Each  plate  was  then  incubated  overnight  at  37°C.    
All  ELISA’s  were  performed  using  respective  eBioscinces  Ready  Set  Go  kits.  ELISA plates were coated 
with 100μl per well of capture antibody diluted in coating buffer. Plate was incubated overnight at 
4°C then washed 4 times in wash buffer. Plate was blocked with 200μl per well of assay diluent (1:5 
in distilled water) for 1 hour at RT. Plate was washed 4 times in wash buffer. 100μl of standard was 
added to the top of appropriate wells, which was then serially diluted 2-fold in assay diluent (1:5 in 
distilled water) with the last well at a concentration of zero. Macrophage culture plates were 
centrifuged at 1400RPM for 10 minutes at 20°C.  50μl of macrophage supernatant from each donor 
was then added neat into wells in replicates of four for each condition. Plate was then incubated at 
RT for 2 hours, then washed four times in wash buffer. 
100μl of detection antibody diluted in assay diluent (1:5 in distilled water) was added to each well 
and the plate was incubated for one hour at room temperature before washing four times in wash 
buffer. 100μL of Avidin-HRP diluted in assay diluent (1:5 in distilled water) to the same concentration 
as respective detection antibody was added and plate was incubated for 30 minutes at room 
temperature. Plate was then washed six times in wash buffer. 100μl of Substrate solution was added 
to each well, plates were incubated at room temperature for 15 minutes before 50μl of Stop 
solution was added. Plates were then read at 450nm in a plate reader. 
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Results 
Peripheral blood was obtained from healthy donors either from volunteers from the lab or from a 
blood cone obtained from the national blood bank. After purification, GM-CSF was added to media 
to induce differentiation of M1 macrophages for 6 days. After this, differentiated macrophages had 
to be scraped off plates for use in the various experiments, with the exception of the cytokine ELISA, 
which used the supernatants. 
Lyp negatively regulates ROS production  
Both Lyp and Vav could potentially regulate the molecules involved in the ROS production. In order 
to study this, we looked at the effect of Lyp inhibition on ROS production. We hypothesised that if 
Lyp does regulate pathways involved in ROS production, its inhibition should result in an increased 
ROS production. To investigate ROS production, we used Dihydrorhodamine 1,2,3, (DHR). DHR 
diffuses into cells where it can be oxidised to fluorescent Rhodamine 1,2,3. This fluorescence is 
therefore a marker of superoxide presence. First, cells were incubated with increasing 
concentrations of Lyp inhibitor for 40 minutes at 37°C. Control cells were incubated without Lyp 
inhibitor. Cells were next incubated with DHR for five minutes before PMA or LPS was added. 15 
minutes later, cells were then analysed for fluorescence by flow cytometry. This experiment was 
repeated three times and the results are plotted below (figure 2). 
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Figure 2: Lyp inhibition and ROS production. Macrophage were pre incubated with various concentrations of Lyp 
inhibitor  (Lyp inh conc µM) were loaded with DHR, then left unstimulated or stimulated with either LPS or PMA. Cells 
were then run on the flow cytometer, with the mean fluorescence of ROS sensitive DHR measured for each sample. The 
experiment was repeated two more times with different donor cells. The baseline fluorescence was noted as the 
fluorescence for unstimulated cells without Lyp inhibitor. The fluorescence for each sample was then compared to the 
baseline fluorescence from the respective experiment and plotted as a ratio. Error bars show standard deviation. 
Statistical analysis performed using graphpad prism 5. A Two-Way ANOVA was performed between the PMA treated 
cells and unstimulated cells. p< 0.001 = ***. 
The level of ROS was found to increase with increasing concentration of Lyp inhibitor. Surprisingly, 
LPS addition did not increase ROS compared to unstimulated cells. PMA addition did significantly 
increase ROS compared to unstimulated cells. These results suggest that Lyp can function to reduce 
basal ROS in resting cells and induced ROS after cell activation by PMA. 
Lyp and calcium flux after FcγR crosslinkage 
We wanted to investigate the role of Lyp in signal transduction after FcγR crosslinkage. For this we 
decided to use calcium flux as an indicator of signalling, since an intracellular calcium increase is 
associated with FcγR ligation. We hypothesised that Lyp inhibition will cause a decreased negative 
regulation of FcγR signal transduction, and therefore greater calcium flux. Cells were incubated with 
Lyp inhibitor at a low concentration of 0.6μm	  and	  the	  higher	  concentration	  of	  1.25μm.  
Control cells were incubated without any Lyp inhibition. At the same time cells were incubated with indo-1 dye, an indicator of free calcium for 40 minutes. While in the fluorometer machine, 
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anti-CD64 was first added, followed by a secondary antibody to crosslink and induce signalling. This experiment was repeated three times, with calcium flux presented as a ratio of calcium before crosslinkage compared to peak calcium after crosslinkage (figure 3). The results from each experiment were non consistent and on the whole no significant difference in calcium flux after CD64 crosslinking at either Lyp inhibitor concentration compared to control cells. 
  
 
Figure 3: Lyp inhibitor and calcium flux after CD64 ligation. Macrophages were pre-incubated with Lyp inhibitor at 
concentrations of 0.6μM or 1.25μM, with control cells incubated without Lyp inhibitor. Cells were incubated with the 
calcium sensitive dye Indo-1 then run in a fluorometer machine in a cuvette, which measures fluorescent output. Anti-
CD64 antibody was added to coat CD64, 100 seconds later the secondary goat anti-mouse antibody was added to 
crosslink the CD64 receptor and induce signalling. After the calcium flux reached basal levels again, ionomycin was 
added as a positive loading control. B) The experiment was repeated two more times with different donor cells. Samples 
have been plotted as a ratio of the peak fluorescence during calcium flux compared to the baseline calcium level before 
antibody addition. 
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Lyp and cytokine production 
 
Primary human T cells expressing the W620 variant of Lyp have altered cytokine production 25. Based 
on this, and the multiple points where Lyp could affect cytokine signalling pathways, we decided to 
investigate the effect of Lyp inhibition on pro-inflammatory cytokine production. We hypothesised 
that Lyp inhibition will result in a decreased negative regulation of pro-inflammatory cytokine 
production. Macrophages where obtained from three separate donors and cells were incubated in 
four conditions: with or without Lyp inhibitor,  and  with  or  without  LPS.  ELISA’s  were  set  up  for 
detection of TNFα, IL1β and IL6 release into supernatant. Each cytokine ELISA was performed in 
replicates of four for each condition for each donor.  
 
 
 
Figure 4: Cytokine productions by macrophages. The three donor macrophages are labelled from D1, D2 and D3. 
Macrophages were incubated overnight in one of four conditions: no LPS, with Lyp inhibitor (red/L-Ly+); no LPS, no Lyp 
inhibitor (blue/L-Ly-); with LPS, with Lyp inhibitor (orange/L+Ly+); with LPS, no Lyp inhibitor (pink/L+Ly-). The following 
day, supernatants were analysed by ELISA for IL1β, TNFα and IL6. Statistical analysis was performed for the no LPS, no 
Lyp inhibitor groups. A repeated measurements one-way ANOVA was performed where p < 0.05 = * and p < 0.001 = ***. 
Surprisingly, the presence of Lyp inhibitor and/or LPS did not seem to stimulate cytokine release, 
with LPS actually decreasing TNFα production (figure 4). One donor was found to have a significantly 
greater cytokine release than the other two donors figure 4. We later learned that this donor is 
heterozygous for the W620 variant (data not shown). This result would suggest that expression of 
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the W620 variant correlates with a decreased negative regulation of cytokine production. Donor 1 
also responded particularly poorly in terms of cytokine production. 
 
 
Regulation of Vav by Lyp 
Since Vav is a substrate of Lyp and since Vav could have a role in the investigated pathways, we 
wanted to see whether Lyp could regulate Vav activity. In order to investigate the role of Lyp in Vav 
regulation, we performed a western blot for phosphorylated Vav in the presence of Lyp inhibition. 
Macrophages were initially incubated with 0.6μm  and  1.25μm  of  Lyp  inhibitor.  Control  cells  were  
incubated without Lyp inhibitor. SDS loading buffer was added directly to whole cells to allow lysis, 
before cells were run. After running and transferring, the blot was initially probed for 
phosphotyrosine (data not shown). However, after getting hold of anti-phosphorylated Vav 
antibody, the blot was stripped and re-probed for this. Thus antibody binds specifically to the 
Tyrosine 174 residue of Vav proteins, phosphorylation here is required for Vav activation and GEF 
activity 35. As a loading control, the blot was re-stripped and re-probed for anti-Vav to allow a 
comparison of Vav protein levels between samples.  
From figure  5,  we  can  see  that  the  sample  of  macrophages  with  a  higher  Lyp  inhibition  (1.25μm)  has  
a less intense stain for phosphorylated Vav than control and the low Lyp inhibitor concentration 
(0.6μm)  cell  samples.  This  is  suggestive  that  a  higher  inhibition  of Lyp activity results in less 
phosphorylation of Vav at Tyr 174. However, the sample of macrophages with the high inhibitor 
concentration has a less intense stain for Vav, suggesting that there was less Vav protein present in 
this sample anyway. It is therefore difficult to interpret whether the higher inhibition results in less 
phosphorylation of Vav. There is no other obvious difference in band intensities between samples. 
There is clear shift in molecular weight between the Vav bands at around 95kDA and phosphorylated 
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Vav bands at around 60kDA. This is surprising giving that both antibodies are supposed to detect Vav 
at its known molecular weight of 95kDA and this further reflects the non-conclusiveness of this 
result.  
 
 
 
 
Figure 5: Lyp inhibition and Vav phosphorylation. Macrophages were incubated with Lyp inhibitor at 0.6μM and 1.25μM 
with control cells (0μM) incubated without Lyp inhibitor. Cells were lysed directly in SDS buffer, then western blot was 
performed. Cells were probed first with anti-phosphorylated Tyr-174 Vav antibody as shown in the upper blot (Phospho-
Vav). The blot was the stripped and re-probed with anti-Vav antibody as shown in the lower blot (Vav). 
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Discussion 
 
Variants of Lyp phosphatase are linked to autoimmune diseases such as rheumatoid arthritis. Studies 
of Lyp have previously only focused on lymphocytes; this is despite the fact that myeloid cells have a 
higher Lyp expression. The purpose of this study was to investigate the role of Lyp in primary human 
macrophages. We used an established Lyp inhibitor and looked at the effects of Lyp inhibition on 
macrophage signalling pathways.  
We found that Lyp inhibition increased the level of ROS in unstimulated and PMA stimulated cells. 
An important cellular source of ROS after PMA treatment is from NADPH oxidase enzymes . Primary 
human macrophages have previously been shown to produce ROS in response to PMA 99. PMA can 
activate conventional and novel PKC isoforms which can phosphorylate and induce translocation of 
p47phox.  In neutrophils,  after  PMA  treatment,  the  conventional  PKCβ  isoform  is  required  for 
NADPH activation 100. The isoform(s) activated after PMA treatment in macrophages is unknown. 
However, primary human monocytes activated by opsonised zymosan use PKCδ to phosphorylate 
p47phox 87. PMA treatment of these  cells  also  caused  PKCδ activation, which could then 
phosphorylate p47phox when  purified  from  cells.  PKCα is also activated and can then positively 
regulate NADPH function by cPLA2 generation in these cells. Further experiments could utilise 
various PKC inhibitors to deduce which isoforms are important in human macrophages. 
The results suggest that Lyp negatively regulates ROS production. Lyp may negatively regulate DAG-
mediated activation of PKC, and thereby ROS production. There are several non-exclusive pathways 
where this could happen. Lyp can dephosphorylate Src family kinases 12,13 and may be capable of 
negatively regulating Vav. Src family kinases can lead to DAG generation. Vav can activate PLCγ  48 
thereby also linking Vav to DAG-mediated PKC activation. Both of these pathways could facilitate an 
increased  basal  ROS  production.  PKCδ  can  negatively  phosphorylate  Lyp,  inhibiting  its activity in T 
cells 27. PKC can also negatively regulate PYPN22 expression in human chronic lymphoid leukemic B 
cells 101 Whether  Lyp  can  interact  with  PKCδ,  or  other  isoforms,  directly  inhibiting  them,  is  unknown.  
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A direct PKC inhibition by Lyp could explain the large increase in ROS with Lyp inhibition of PMA 
treated cells.   
Vav is also involved later in the ROS pathway. Vav has been implicated with roles on ROS production 
through Rac activation 102-105. Vav deficient murine primary macrophages fail to produce ROS after 
LPS induction 102. It was shown Vav GEF activity is required here to activate Rac2. In primary murine 
neutrophils, Vav1 and 3 are required in ROS production  after  FcγR  ligation  103. Again, Vav was 
required for Rac activation here. In human neutrophils, Vav1 can directly interact with the NDAPH 
subunit P67phox where it activates Rac2 after fLMP stimulation106. Rac activation is essential in 
allowing Rac binding to P67phox as well as membrane-bound cytochrome b, which is required in 
NADPH oxidase activation 37.  
Vav is not required for PMA induced ROS production by murine macrophages 102, suggesting Lyp 
function through Vav activation is not responsible for the increased ROS with Lyp inhibited PMA 
treated  cells  in  this  study.  Interestingly,  FcγR  signalling  in  DC’s  activates  NADPH  oxidase,  allowing  
ROS production important in cross presentation 105. This pathway also requires Vav. With the 
requirement of Src family  kinases  in  FcγR  signalling,  it  is  possible  Lyp  could  regulate  Vav  in  DC’s.  It  
would  have  been  interesting  to  investigate  the  FcγR  pathway  and  ROS  in  this  study.  This  area  can  be  
addressed in future studies. 
We found LPS to have no effect on ROS production compared to unstimulated cells. This is despite 
previous studies reporting rapid and detectable ROS levels for hours after LPS stimulation at similar 
concentrations in murine macrophages 107-109 as well as primary human monocytes 110 and 
macrophages 104. These reports used different methods of detecting ROS, including different dyes 
and using plate readers to measure fluorescence. These different methods could account for the 
different results.  
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We also found that the addition of LPS failed to effect pro-inflammatory cytokine production by 
macrophages. Again this was surprising, especially since LPS has been shown numerous times to 
induce  cytokine  production,  including  TNFα,  in  primary  human macrophages 111. Together, this 
indicates that macrophages may have been previously been activated by LPS, possibly during the 
differentiation incubation, and therefore no longer responsive to this signalling pathway. This 
pathway may even have begun to downregulate itself, which could explain the decreased  TNFα  we  
found with LPS stimulation. The use of antibiotics in the culture medium during macrophage 
differentiation could have resulted in release of LPS from any present gram-negative bacteria.  
Antibiotics could be avoided during the incubation, but it is likely any present gram-negative bacteria 
will multiply and shed LPS into the media anyway. Future experiments involving LPS could utilise 
monocytes that can be used right after purification, avoiding the differentiation incubation. 
We were surprised to find no significant difference in calcium flux after CD64 ligation with Lyp 
inhibition. Experiments using another Lyp inhibitor in Jurkat T cells have found an increased calcium 
flux with increased Lyp inhibition after TCR ligation 112. Our lab using the same inhibitor in this study 
has also found an increased calcium flux with increased Lyp inhibition in jurkat T cells (unpublished 
data, R. Bayley). We therefore expected an inhibition of Lyp activity to cause a decreased negative 
regulation of Src family kinases, thereby allowing a stronger CD64 signal transduction, as indicated 
by calcium flux.  
Due to variation between experiments, results are inconclusive. In one experiment, a high Lyp 
inhibitor concentration did result in a greater calcium flux than control cells. In another experiment, 
the high Lyp inhibitor concentration gave a lower calcium flux than control cells. This may have been 
caused by differences in genetic polymorphisms between donor cells. This experiment needs to be 
repeated to investigate if any of these trends are continued.  A greater concentration range would 
also allow a more in depth analysis. 
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This is the first report of macrophages expressing the W620 variant. These macrophages displayed a 
much greater production of the pro-inflammatory  cytokines  TNFα,  IL1β  and  IL6. This lab has also 
seen  that  CD4  T  cells  from  W620  carriers  have  an  increased  TNFα  and  IFNγ  production  (unpublished 
data, R. Bayley). It has previously been reported that primary CD4 T cells expressing the W620 
variant have decreases in IL2 23,24 and IL10 24 production after TCR stimulation, other cytokines 
tested,  including  TNFα  showed  no  difference  between PTPN22 genotypes 24, A decreased IL10 
expression has also been described in unstimulated, un-purified peripheral leukocytes from donors 
with the W620 variant with Anti-neutrophil cytoplasmic antibody disease 113. This decrease 
correlated with an increased basal W620 Lyp phosphatase activity and decreased ERK 
phosphorylation. In contrast another study found stimulated or unstimulated  PBMC’s  from  W620  
homozygotes and carriers showed no difference in cytokine production, including IL10, compared to 
healthy controls 25.  
Our results from primary macrophages expressing the W620 variant differ from these previous 
published reports of primary cells.  The unpurified leukocytes and the PBMC’s  from  the  previous 
reports 25,113 would have lacked macrophages since peripheral blood was used, with no macrophage 
differentiation stage. It is interesting that from the unpurified leukocyte report, the increased basal 
W620 activity also correlated with an increased P38 MAPK phosphorylation 113. 
As  mentioned  earlier,  P38  MAPK  is  important  at  least  in  TNFα regulation in macrophages. If P38 
MAPK is also increased in variant expressing macrophages, this could explain our unique results and 
would highlight the importance of macrophages in driving the inflammatory response seen in the 
synovium of RA patients. Interestingly, the knockdown of Lyp expression in the human monocytic 
cell line THP1 resulted in a greater MAPK phosphorylation with increased IL6 and IL17 22. Our 
experiment needs to be repeated with more W620 variant donors and controls and to compare the 
phosphorylation levels of different MAPKs and also look into regulatory cytokine production such as 
IL10.  
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It should be noted that our donor was healthy, despite Lyp W620 expression, demonstrating that 
other factors can contribute to autoimmune risk with Lyp W620. It would be interesting to find out 
what differs between healthy and autoimmune prevalent carriers of Lyp W620, be it environmental 
or further genetic predispositions. Donor 1 from this experiment did not appear to produce a 
detectable amount of cytokine with the exception of small amounts of  Ilβ  in  some  of  the  replicates.  
This may only have been an experimental artefact and I would suggest donor 1 cells to have been 
dead.  
There are several possible reasons why Lyp inhibitor had no effect on cytokine production. Firstly, 
Lyp may not be a negative regulator of pro-inflammatory cytokines. Though the exceedingly high 
cytokine production seen with the W620 variant expression would argue against this, other genetic 
polymorphisms from this donor could be responsible for the higher cytokine production. Yet the 
report of increased IL6 and IL17 from THP1 cells after Lyp knockdown would dispute this 22. The Lyp 
inhibitor is a reversible competitive inhibitor 98. Hence a more likely explanation would be that the 
inhibitor could have been out-competed and possibly degraded during the overnight incubation.  
We hypothesised that Lyp can regulate Vav activity by directly dephosphorylating it. We therefore 
expected Lyp inhibition to result in an increased Vav phosphorylation at Tyr-174, but this was not 
seen. Although it looked like a higher inhibitor concentration resulted in less Vav phosphorylation, it 
is possible there was less Vav protein present in the sample as suggested by the subtle difference 
Vav in band intensities.  A decreased phosphorylation could indicate Lyp to be a positive regulator of 
Vav activity, where it can directly dephosphorylate inhibitory Tyrosine residues, thereby allowing 
Vav phosphorylation on activation tyrosines such as Tyr-174.  
On top of the many technical issues with the blot as discussed below, the reliability of this 
experiment is further questioned giving that the phosphorylated Vav antibody gave a bands at 
around 50kDA instead of the expected 95kDA. It is unlikely due to Vav degradation since the Vav 
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antibody  only  gave  bands  at  Vav’s  full  molecular  weight  of  around  95kDA.  I  have  no  reasonable  
explanation for this phenomenon. 
Despite the stripping process, the original phosphotyrosine stain is still visible within the lanes, thus 
questioning the efficiency of the stripping. Poor stripping could have resulted in the different band 
intensities between samples. Ideally, an immune-precipitation for Vav should be performed after cell 
lysis. In order to further investigate Lyp regulation of Vav, the western blot process will need to be 
optimised and repeated. Again, a greater range of Lyp inhibitor concentrations could give more in 
depth results. 
The Lyp inhibitor used is a competitive reversible inhibitor of PTPs with a ten-fold selectivity for Lyp. 
The problem with such an inhibitor is therefore the specificity, especially at higher concentrations. 
Ideally, the lab would like to specifically knockdown expression of PTPN22 mRNA in macrophages. If 
this technique can be mastered then experiments could be repeated with PTPN22 knock-down cells. 
This would be a more effective way of showing that Lyp does have a role in macrophage signalling 
pathways.  
In conclusion, this is the first report that Lyp does have a role in primary human macrophage 
signalling pathways. By using a Lyp inhibitor, we have shown that Lyp is a negative regulator of ROS 
production in unstimulated and PMA stimulated cells. The role of Lyp in calcium signalling after CD64 
ligation and in Vav activation remains unknown. We also provide evidence that the Lyp W620 variant 
expression in macrophages allows a greater production of pro-inflammatory cytokines. This has 
implications in understanding how the W620 risk allele can function in autoimmune diseases such as 
RA. 
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 Abstract 
 
During the B cell immune response, extrafollicular foci form after an initial proliferative burst which 
become a site of early plasma cell production. The NP-Ficoll immune response is a T-independent 
reaction, which results in significant extrafollicular foci formation. The NFκB member, cRel, is 
important in activated B-cell  proliferation  and  survival.  It’s  also  been shown in vitro to be important 
in class switch recombination (CSR) and induction of IRF4. IRF4 is essential in plasma cell 
differentiation as well as CSR. 
We showed that after NP-Ficoll immunisation, cRel -/- (KO) B cells produce far less plasma cells. And 
this coincided with low NP-specific antibody production, particularly IgG isotypes. Despite this low 
plasma cell production, WT mice receiving KO or WT B-cells had similar splenic Irf4 levels.  Splenic 
levels of immunoglobulin switch and Aid transcripts, both essential in CSR, were similar. Fluorescent 
staining also showed a similar frequency of WT and KO plasma cells had switched to IgG expression. 
Together, this project shows that despite the defect in plasma cell production with the B-cell 
intrinsic loss of cRel, the few plasma cells which are produced are still capable of CSR. However, the 
low numbers mean actual antibody production is low. 
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 2 
Introduction  B cells are an essential component of the adaptive immune system. Antigen recognition through the B cell receptor (BCR) can facilitate B cell activation and differentiation into short or long-lived antibody-secreting plasma cells or into memory B cells. The B cell immune response may be thymus dependant (TD) and require cognate T cell help or be thymus independent (TI), not requiring T cells. TI type 1 (TI-1) reactions involve B cell activation through mitogenic signals such as TLR signalling. TI type 2 (TI-2) involves extensive BCR crosslinking through repetitive epitopes, typical of polysaccharides.   The mature naïve B cell pool is heterogenic in phenotype as well as function 1. The majority are recirculating follicular B2 B cells (FO B cells), which circulate the secondary lymphoid organs (SLO), homing into primary B cell follicles. Here, networks of follicular dendritic cells (FDCs) can present antigen. FDC production of the chemokine CXCL13 attracts the CXCR5hiCCR7lo FO B cells into the follicles 
2. T cells, in contrast are CXCR5loCCR7hi, allowing accumulation into CCL19 and CCL21 rich T cell zones.   T zones are found next to follicles and this arrangement of lymphocyte rich zones make up the white pulp in the spleen, the cortex and paracortex of lymph nodes and appear in organized mucosal associated tissues. FO B cells typically respond in a TD manner. A marginal zone (MZ) consisting of B cells and macrophages surrounds the white pulp edge between the marginal sinus and the red pulp 3. The red pulp is a red blood cell, reticular cell, and macrophage rich zone important in blood filtration. 
 3 
 MZ B cells are another B2 cell subset 3. These cells show a pre-activated phenotype, can self renew and do not recirculate. They can however capture immune complex via CD21 and transport it into follicles transferring it to FDC. Positioned next to the marginal sinus, these cells are important in rapid TI responses to blood-borne antigen. B cells of a similar phenotype have been described in lymph nodes,	  Peyer’s	  patches	  and	  tonsils 4. B1 B cells as described in mice include the CD5+ B1a cells and the CD5- B1b cells 5. These cells are the main B cell population in the peritoneal and pleural cavities while rare in the spleen and lymph nodes. They are the major producers of natural antibody, an important first line of defence to infection. They may be activated with or without BCR stimulation to form plasma cells that produce IgM or IgA. 
The B cell immune response 
 FO B cells enter the follicles where they reside for around 24 hours before recirculating to another secondary lymphoid organ. Should they encounter specific antigen within the follicle, or even free antigen in the blood or lymph, FO B cells will migrate to the follicular-T cell border. Likewise, should MZ B cells recognise antigen, they will also migrate to the T cell border 4 6. An upregulation of CCR7 by antigen activated B cells allows this migration 2.  Likewise, during a TD response, dendritic cell (DC) primed CD4 T cells upregulate CXCR5 to meet cognate B cells.   
 4 
At this border, the B cells receive proliferation and differentiation signals. During a TD response, B cells present processed antigen via MHC class II molecules to cognate CD4 T cells by 12 hours 4. This cognate interaction initiates reciprocal survival signals, including B cell CD40 engagement 7. CD11hi DCs are also present at the border and can provide BAFF or APRIL survival signals 8. This could be particularly important in TI B cell survival. Innate helper cells including neutrophils 9, NK cells 10 and iNKT cells 11 can also provide help in TI and TD responses as can microbial TLR signals.  After 1 to 2 days here, B cells begin proliferation at the border 8,4. Clones may undergo as little as two cell cycles 4 although reports include at least three divisions two days into a TD response 12. Class switch recombination (CSR) from IgM to other Ig heavy chain classes can also occur during this proliferation between days 2 and 3, but is restricted to B blasts 12 46. After this short proliferative burst, B cells move into the splenic red pulp or lymph node subcapsular interfollicular areas then form extrafollicular foci, or move into follicles and initiate germinal centres 12,4.    The extrafollicular foci is a site of early and rapid plasma cell differentiation. This starts with B blasts differentiation into proliferating and low antibody producing plasmablasts, followed by terminal differentiation into plasma cells 4. Early recirculating memory cells can also form from these foci 12. Plasma cells produced here are typically short lived. The germinal centre (GC) is a dedicated site for cycles of further B cell proliferation, affinity maturation and CSR of the BCR with selection of high affinity clones. These clones can then contribute to 
 5 
plasma cell and memory cell differentiation 4 13. GC’s	  are	  classically thought of as TD, but TI non-productive	  GC’s	  can	  occur	  under	  certain	  circumstance	  14. 
Plasma cell differentiation   Differentiation of plasma cells requires a complex transcriptional network including Blimp1, XBP1 and IRF4. Blimp1 has been described as the master regulator of plasma cell differentiation. Transfection of this zinc-finger transcriptional repressor into B cell lines can induce differentiation into a plasma cell phenotype 15. Blimp1 was further clarified as a master regulator when mice whose B cells lacked Blimp1 failed to produce plasma cells or produce antibody sufficiently 16.   Blimp1 inhibition of c-myc 17 halts the cell cycle allowing terminal differentiation. Blimp1 can inhibit genes involved in B cell function and GC differentiation including Pax5 and Bcl6 18. Pax5 is expressed throughout B cell subsets but not in plasma cells 18. It can activate genes involved in B cell function, including BCR signalling, while repressing genes associated with plasma cell differentiation, including XBP1 18.   XBP1 activates genes involved in the secretory apparatus, essential in antibody secretion 18.  Inhibition of Blimp119 therefore allows XBP1 activation and function 20 while helping shut down B cell function. Therefore downregulation of Pax5 is necessary for plasma cell differentiation. However one paper describes 
how	  the	  initial	  downregulation	  of	  Pax5	  is	  independent	  of	  Blimp1	  with	  B	  cell’s	  
 6 
lacking Blimp1 capable of differentiating into a low antibody secreting pre-plasmablast stage 21.   Bcl6 is highly expressed in GC B cells. Here it acts as a master regulator allowing high levels of proliferation and repressing DNA damage response to allow BCR affinity maturation, while repressing Blimp1 expression and preventing plasma cell differentiation 18. Blimp1 can reciprocally repress Bcl6 22 to prevent GC B cell state. It also represses genes involved in CSR, which are	  highly	  expressed	  in	  GC’s 
22. The repression of Bcl6 is important in preventing GC B cell differentiation and a downregulation of Bcl6 is particularly important in exiting the GC state. IRF4 is another transcription factor now appreciated to be essential in plasma cell development as discussed in the next section. 
IRF4 in B cells  IFR4 is a transcription factor capable of interacting with a variety of co-factors 23. The best described cofactor interaction is that of PU.1 and also the closely related SPI-B. Dimer interactions with these co-factors are important in the transcription of IgH and IgL-κ loci. The role in immunoglobulin production is further exemplified in Irf4 KO mice 24. Despite a normal B cell development, these mice exhibit extremely reduced serum immunoglobulin levels and fail to produce a detectable antibody response to immunisation.   Human and mouse lymphoid tissue histology later showed how IRF4 expression was high in plasma cells but largely absent from GC B cells 25,26. The IRF4 
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expressing GC B cells appear to be centrocytes in the light zone and most co-express Blimp1 27. This is suggestive that these cells are precursors of plasma cells. There is now good evidence to show IRF4 is required in plasma cell differentiation. It was shown in vivo that plasma cell differentiation	  from	  GC’s	  required IRF4 expression 28. Despite lack of IRF4, Blimp1 was still upregulated, but not sufficient for plasma cell development, suggesting IRF4 to work in parallel to Blimp1. Another study found that B cells lacking IRF4 activated in 
vitro also failed to differentiate into plasma cells 29. These cells failed to upregulate Blimp1 suggesting IRF4 is upstream of Blimp1.  This difference in where IRF4 functions with Blimp1 is likely due to the different experimental systems used. There is also evidence that Blimp1 can activate IRF4 expression 30. Negative regulation of IRF4 by MITF occurs in naïve B cells 31 and can be upregulated during B cell activation via NFκB 3233. Both studies also described how CSR was inhibited, due to a failure to upregulate AID, which as described next, is essential in CSR.  
AID, CSR and IRF4  CSR, as reviewed elsewhere 34, is the process of switching to another heavy chain constant region, thereby producing antibody of different effector functions. This process occurs through a recombination event between switch regions, located upstream of each heavy chain constant gene loci, with deletion of the intervening DNA. AID is responsible for de-aminating cytosines to uracil bases in each switch region. Uracils are subsequently removed and nicks are incorporated into the 
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DNA by further proteins. Mismatch repair proteins then facilitate end join recombination.   Transcription is required through the switch region, beginning at the I exon upstream of the switch region and continuing through the CH locus. This transcript, known as the switch or germline transcript must then be spliced to bring the I exon to the first CH exon to allow productive CSR 35,36. The transcript is not thought to code a protein and its functional role is not known, but may form DNA-RNA hybrids to open the switch region and allow CSR. 34.  AID is positively regulated by Pax5 37 and negatively regulated by Blimp1 22. IRF4 is also required for AID expression during CSR 28,29. AID is expressed in GC founder cells and GC B cells. AID is also expressed in some B blasts of the extrafollicular response, allowing CSR before it is repressed in plasmablasts and plasma cells 6. Based on IRF4 transduction rescue experiments with IRF4 KO B cells, its been proposed a low/intermediate IRF4 level allows CSR but not plasma cell differentiation 29. As Blimp1 and IRF4 levels increase, plasma cell differentiation is initiated with AID and CSR is inhibited. 
cRel  The NFκB transcription factor family consists of five proteins: p65-RelA; RelB; cRel; p105/p50; and p100/p52 38. These proteins form various dimers capable of regulating the transcription if genes involved in an array of processes such as cell proliferation, differentiation and survival. Dimers are usually found in the 
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inactive state bound to inhibitory κ B (IκB) within the cytosol. Cell signalling events can result in phosphorylation of IκB’s	  by	  IκB kinase (IKK) followed by IκB degradation, allowing NFκB translocation and target gene regulation.  One interesting NFκB family member is cRel, which commonly forms homodimers and dimers with p50 and less often with p65-RelA and p52 39. cRel has a more promiscuous DNA target sequence recognition and can bind different residues than the other NFκB members 40. In immature B cells, cRel is low but becomes the main dimer, in the p50-cRel form in mature B cells. cRel knock out mice have revealed much about cRels requirement for T and B cell immune functions. In particular, KO mice have reduced B cell proliferation and survival to stimulation with LPS, anti-IgM, anti-CD40 and antigen. Antibody production is 
also	  reduced,	  and	  GC’s	  are	  found	  to	  be	  small/irregular	  39.   cRel allows proliferations through cMyc activation in the G1 phase and allows movement to the S phase. cRel also prevents apoptosis through activation of the 
Bcl-2 anti-apoptotic gene family. There is also evidence cRel allows B cell isotype switching by initiating and enhancing transcription through S regions 4142,43. Intriguingly, in cRel KO mice, B and T cells fail to upregulate IRF4 in response to various mitogens 33. Thus cRel regulation of IRF4 could represent another way it might facilitate CSR.   
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This project  The Toellner lab is interested in the early events of the B cell immune response. In this project, we are investigating the B cell immune response to the TI antigen NP-Ficoll. By using cRel -/- mice and adoptive transfer of cRel -/- B cells, we hypothesised that the absence of cRel  will result in defects in the production of NP-specific plasma cells. We also hypothesised that the absence of cRel will result in poor induction of Irf4 and Aid transcripts as well poor induction of CSR.                                  
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Materials and methods  
Mice and immunisations  All mice used were males aged 6 to 8 weeks old and maintained in specific pathogen-free conditions at the Biomedical Services Unit at the University of Birmingham, UK and treated according to The Home Office guidelines.   In the first experiment, C57/BL6 mice were used. c-Rel+/+ wild type and c-Rel-/- knock out mice were immunised via intraperatoneal (i.p) injection of NP-Ficoll (Bioscearch Technologies, CA) dissolved in PBS at 30μg/200μl	  per	  mouse. NP-Ficoll gives a T-independent response useful for specifically studying a B cell response. Cohorts of mice were then sacrificed at day 0 (before immunisation) and day 5 and 7 after immunisation.  QM (quasi-monoclonal) mice have the NP-specific rearranged 17.2.25 VHDJH segment on one allele, with a JH deletion on the other allele and deletion of the Jk loci 44.  This results in around 95% of the B cells expressing NP-specific B cell receptors. QM mice used here also express enhanced yellow fluorescent protein (eYFP) in every cell 45. These mice were crossed onto the wild type (c-Rel+/+) or knock-out (KO) (c-Rel-/-) C57/BL6 background. Naïve mice were then used to provide naïve B cells for the cell transfer experiment.   Wild type C57/BL6 mice received cell transfer by intravenous (i.v) injection. The 2 hour and day 2 cohort received 1x106 cells, with the day 5 cohort receiving 4x105 cells from the wild type or knock-out QM donors. KO C57/BL6 recipient 
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mice also received 4x105 wild type QM donor cells. 24 hours later, all mice received an NP-Ficoll immunisation by i.p injection at 30μg/200μl per mouse.  The respective cohorts were then sacrificed at 2 hours, 2 days and 5 days after immunisation. The KO recipient mice were also sacrificed at day 5. 
Cell transfer  Spleens were removed from four wild type and four knock out QM mice. Spleens were mashed in media (RPMI 1640, penicillian streptomycin and 10% fetal calf serum (all sigma)) then centrifuged at 1200RPM for 5 minutes at 24°C. Supernatant was removed and cells were pooled together into wild type and knock out splenocytes. Red blood cells were lysed by addition of 1ml of ACK lysing buffer (Invitrogen) per spleen for one minute before topping up to 5mls with media then centrifuging as before. Splenocytes were then resuspended in MACs buffer then counted in 10% Trypan Blue to differentiate live and dead cells. Splenocytes were then sorted using CD43 beads (Miltenyi Biotech) according to manufacturers instructions. CD43 is expressed on non-B cells and activated B cells, allowing a negative selection of naïve B cells that pass through the MACs column.   
Flow cytometry  For antibodies, see appendix table 1. Mice were sacrificed at the indicated times. All steps performed on ice or at 4°C. Sections of spleen were mashed in media into a single cell suspension, then 
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filtered through a 70μl cell strainer then washed twice in media by centrifugation at 1200RPM for 5 minutes. 1x106 cells from each splenic sample as well as some to represent single colour/unstained controls were resuspended in 200μl of FACS buffer (sterile PBS with 0.5% FCS and 0.2mg EDTA). Cells were first stained with Hoechst nuclear dye (1/3000) in FACs buffer which stains high in dead/dying cells. After quickly washing in FACS buffer, cells were stained with FC receptor II/III block at 1/200 in FACS buffer for 20 minutes. After washing, fluorescently conjugated antibodies were added to samples and appropriate antibody added to single stain controls, diluted in FACS buffer to the cells for 30 minutes. After washing in FACS buffer twice, cells were resuspended in FACS buffer, transferred to FACS tubes then run in a Dako Cyan analyser and FlowJo software (FlowJo, Ashland, OR). Around 5x105 events were collected for each sample 
Immunohistochemistry  For all antibodies, buffers and substrates see appendix tables 2, 3 and 4.  6μm spleen sections were cut onto glass slides then fixed in acetone for 20 minutes at 4°C.  Slides were washed in Tris pH 7.6 for 10 minutes. Slides were then stained with unconjugated primary antibodies diluted in Tris pH 7.6 for one hour then washed in Tris pH 7.8 for 5 minutes. Secondary antibodies were 
incubated	  with	  10μl	  normal	  mouse	  serum	  (Dako,	  UK)	  in	  90μl	  Tris	  pH	  7.6	  for	  30	  minutes at RT before adding more Tris pH 7.6 to make final dilution. Secondary antibodies were added to slides for 45 minutes before washing again for 5 
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minutes. The tertiary Vectastain ABC-AP kit (Vector Laboratories, USA), with solution A and B added to Tris pH 7.6 (1/100) was added to the slides for 30 minutes before another 5 minute wash. Slides were then stained with peroxidase substrate until colour was present. Slides were washed for 5 minutes again then stained with Alkaline-phosphate substrate until colour was present. Slides were then washed one final time before rinsing twice in distilled water. Slides were air dried then cover slips were secured on top with gelatine (Sigma). Pictures were taking with a Leica CTR6000 microscope with micropublisher 5.ORTV camera using Q Capture software.  
Quantification  Slides were viewed under a light microscope. NP positive cells present within the red pulp were classified as NP-specific plasma cells for quantification. At early time points, single cells were counted. At later time points, a point counting technique was used where plasma cell foci that crossed the bottom right corner of each square were counted. The number of these intersects were then multiplied by the average number of plasma cells present within three typical foci. For each mouse, half the spleen area was used for quantification. 
Fluorescent staining for immunoglobulin switching  For antibodies, see appendix table 5  
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Slides were cut and fixed as above. All wash steps were performed in PBS and all staining/blocking was performed with reagent diluted in a 10%BSA in PBS buffer. First slides were washed for 5 minutes then slides were blocked in 10% normal horse serum. The primary Rat anti-mouse IgG was then added at 1/200, with a control section receiving buffer only for 1 hour. After washing for 5 minutes, slides were stained with the secondary donkey anti-rat-Cy3 for 45 minutes. Slides were then washed for 30 minutes in PBS then blocked for 20 minutes in normal rat serum. Then slides were stained with anti-IgD-PB; rat idiotype-Cy5 and goat anti mouse IgM-FITC  for 45 minutes (antibodies were first incubated with 10% normal rat serum for 30 minutes). Slides were then washed for 5 minutes before coverslips were attached using ProLong Gold antifade reagent (Invitrogen). Slides were stored at -20°C until required.  Pictures were taking with a Leica CTR6000 microscope. For quantification, ten plasma cell foci were photographed at x20. For each foci, 10 to 15 idiotype plasma cells were counted. It was then determined whether or not these cells co-stained for IgG. 
Taqman real time PCR  For reverse transcription mix and for primers and probes, and primer array details, see appendix tables 6 and 7.  8μm spleen sections were cut on the cryostat. Sections were disrupted and homogenised using the QIAshredder columns and mRNA was prepared using 
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RNeasy mini kits according to manufactures instructions (both Qiagen). RNA was stored at -80°C if not used straight away. To generate cDNA, 3μl of random primer (Promega) was added to 30μl of the mRNA. Sample was then denatured at 70°C for 10 minutes before cooling on ice. 27μl of a reverse transcription mix was then added to each sample before a one hour incubation at 41°C followed by 10 minutes at 90°C.   cDNA was stored at -20°C if not used straight away. 0.5μl of each cDNA sample was added into a 384 well plate with 5μl of the appropriate probes and primers specific to the target gene or the housekeeping gene (β2-microglobulin) and Taqman PCR master mix. The plate was run in an ABI 7900 real-time PCR machine (Applied Biosystems). The PCR cycle was 50°C for 2 minutes, 95°C for 10 minutes followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute.  Data was analysed using the SDS 2.2.2 software (Applied Biosystems) to set the thresholds. The quantification cycle (Cq) for each samples target and housekeeping gene was noted, then the target gene was quantified by removing the housekeeping Cq from the target Cq then taking the square root of this value. 
ELISA  For all antibodies and serum dilutions, see appendix tables 8 and 9.  Blood was removed from mice at the respective times by cardiac puncture. After centrifuging at 13000RPM for 10 minutes at 24°C, serum was removed then 
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stored at -20°C until required. Coating buffer (15mM Na2CO3; NaHCO 35mM) with NP2BSA or NP15BSA (both made in house) at a concentration of 5μg per ml was added to 96 welled plates (Nunc, Thermo Scientific) at 100μl per well. Plates were incubated at 4°C overnight before washing three times in wash buffer (PBS 100mM; 0.05% Tween 20). Plates were then blocked in blocking buffer (PBS with 1% BSA), at 200μl per well for one and a half hours at 37°C before washing again three times. For detection, mouse serum, a negative control serum and a positive control serum were diluted in diluting buffer (blocking buffer plus 0.05% Tween 20). The negative control was an unimmunised Cγ1 CRE mouse aged 2-6 weeks. The positive control was day 5 of a CGG primed NPCGG boosted BALB/C mouse.  Serum was serially diluted in blocking buffer down the plate. The plate was incubated for one hour at 37°C before washing three times. Isotype specific detection antibody diluting buffer was added at 100μl per well for one hour at 37°C.  For non-AP conjugated detection antibody, after washing three times, Alkaline-phosphatase streptavidin (Vector) in dilution buffer was added (1/500) for one hour at 37°C. After washing three times, 100μl of p-nitrophenyl phosphate (N2770, Sigma) was added to wells for 30 minutes at 37°C. Plates were then read at 405nm using Synergy HT Microplate Reader (Bio-Tek, USA. 
Statistics  The Mann-Whitney test was performed using graphpad prism 5 where appropriate. 
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Results 
cRel knock-out mice produce less NP specific plasma cells  In the first experiment, wild type (WT) and cRel knock out (KO) mice of the C57/BL6 background were immunised with NP-Ficoll with the exception of the day 0 cohort as an unimmunised control. The respective cohorts were then sacrificed at day 0, day 5 and day 7 for analysis.  Immunohistology of the spleen was performed. NP positive cells that were present in the red pulp were classified as red pulp plasma cells/plasmablasts. By day 5, foci of large numbers of NP-specific plasma cells were prevalent in WT spleens and were of similar size by day 7 (figure 1). In contrast, day 5 KO spleens had fewer foci containing less cells. By day 7, foci were still rare, but more cells were present in the clusters, suggesting a low level of proliferation has occurred.   NP-specific red pulp plasma cells were quantified from labelled tissue sections (figure 2). Plasma cells were significantly higher than background and KO mice by day 5 in WT mice with a median around 50-fold greater than in KO mice. NP-specific plasma cells were not above unimmunised background level until day 7, although the difference is non-significant. However in KO mice the median is now only about 5-fold lower than the WT day 7 mice. There is some variation at day 7 in the KO group, with one mouse still at background levels and one mouse at a similar level to the WT day 7 group.   
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Figure 1: NP-specific plasma cells of the splenic red pup. WT and cRel -/- (KO) mice immunised with 
NP-Ficoll then sacrificed at the indicated time points. Spleens were sectioned and Immunohistology 
was performed. Sections on the left were stained for CD3 (blue) and IgD (brown); sections on the 
right were stained for NP binding (blue) and IgD (brown). Arrows indicate clusters of NP-specific 
plasmablasts/plasma cells.  Also indicated is the red pulp (RP), follicle (F) and the T cells zone (TZ). 
All images taking at x20 and the scale is representative for all images.   
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Figure 2: splenic red pulp NP specific plasma cells/blasts. WT (blue) and cRel -/- (KO) (red) mice 
immunised with NP-Ficoll, with the exception of the day 0 cohort, left as an unimmunised control. 
Immunohistology was performed on splenic sections at the indicated time points. Red pulp NP 
specific plasma cells/blasts were quantified from half the spleen area. Data shows the individual 
mouse values for NP plasma cells per mm2. The black lines within each group represent the group 
median. Statistical analysis involved the Mann-Whitney test between the two indicated groups as 
shown by the bar, where p<0.05 = * and ns = non significant.  
cRel knock-out mice produce a lower NP-specific antibody response  Serum was taken from sacrificed mice and ELISA was performed for NP-specific antibody as shown in figure 3. NP-specific antibody is present in the unimmunised control, for WT and some KO mice. This is likely to be low affinity natural antibody and not specific to an NP immune response. In WT mice high IgM levels are seen by day 5, which increase to day 7. Low but significant titres of IgG are detectable by day 5 in WT mice, with a large increase seen at day 7. WT mice also produced detectable IgG1 from day 5. IgG2a is only detectable at low levels, in two WT mice and one KO at day 7.  In contrast, KO mice show a consistently lower NP-specific antibody level. KO mice have significantly reduced IgM levels at day 5 and 7 compared to WT, 
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although levels have increased in some KO mice at day 7. KO Total IgG levels are also significantly reduced compared to WT and similar to background levels at day 5. Again, some KO mice have increased levels by day 7. KO IgG3 is actually similar to WT at day 5, except from one mouse with non-detectable levels. By day 7, levels have increased although the group is still below WT. IgG1 is also undetectable in KO mice at day 5. Only one KO mouse gave IgG1 by day 7.   Although antibody levels do seem to increase a little from day 5 to day 7 in the KO groups, it is still lower than WT. The exception to this is one KO mouse from day 7, which was consistently high in antibody titre and NP-specific red pulp plasma cells (figure 2). This genotype of this mouse was confirmed to be cRel-/- (personal communication, Laura George).      
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Figure 3: NP-specific antibody ELISA. WT and cRel -/- (KO) mice immunised with NP-Ficoll, with the 
exception of the day 0 cohort, left as an unimmunised control. Mice were sacrificed at the indicated 
time points. Serum was taking at the indicated time points and ELISA performed for various 
antibody isotypes. Each data point represents a single individual mouse value. The black lines 
within each group represent the group median. Statistical analysis involved the Mann-Whitney test 
between the two indicated groups as shown by the bar, where p<0.05 = * and ns = non significant.  This experiment shows that in the absence of cRel, there are defects in extrafollicular plasma cell production and defects in specific antibody production in response to NP-Ficoll. However, it is unknown whether this is due to defects in the B cells themselves (B cell intrinsic) or of the supporting stromal environment. In order to investigate this, an adoptive transfer experiment was performed. QM mice have a B cell repertoire with around 95% BCR specific to NP 
44. Naïve splenic B cells (CD43 negative) from WT QM mice and cRel KO QM mice were adoptively transferred into WT C57/BL6 mice. Mice were immunised with NP-Ficoll then sacrificed for analysis at 2 hours, 2 days and 5 days after immunisation. As a control, WT QM cells were also transferred to cRel KO C57/BL6 mice, before immunisation as above then analysis at day 5 only.  
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cRel KO transferred B cells form less extrafollicular foci of plasma cells  Immunohistology of the spleens was performed as before. Anti-idiotype was used to specifically identify transferred cells. Extrafollicular foci of idiotype plasma cells was not evident until day 5, at which point, mice that received WT cells had a greater number of splenic red pulp plasma cells, with the median around 6 fold greater than in KO>WT mice (figure 4 and 5). WT cells gave the same number of plasma cells whether in a WT or KO environment (figure 5), suggesting that the main role of cRel is B cell intrinsic.   
 
Figure 4: idiotype specific plasma cells of the splenic red pup. Naïve B cells from WT QM and cRel-/- 
(KO) QM mice were transferred into WT (WT.QM>WT), (KO.QM>WT) or KO hosts (WT.QM>KO). Mice 
were then immunised with NP-Ficoll. Immunohistology was performed on splenic sections 5 days 
later. Sections on the left were stained for CD3 (blue) and IgD (brown); sections on the right were 
stained for transferred cell idiotype (blue) and IgD (brown). Arrows indicate clusters of NP-specific 
plasmablasts/plasma cells.  Also indicated is the red pulp (RP), follicle (F) and the T cells zone (TZ). 
All images taking at x20 and the scale is representative for all images. 
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Figure 5: idiotype NP-specific plasma cells. Naïve B cells from WT QM and cRel-/- (KO) QM mice were 
transferred into WT or KO hosts. Mice were then immunised with NP-Ficoll. Immunohistology was 
performed on splenic sections at the indicated time points. Red pulp NP specific plasma cells/blasts 
were quantified from half the spleen area. Data shows the individual mouse values for NP plasma 
cells per mm2. The black lines within each group represent the group median. Statistical analysis 
involved the Mann-Whitney test between the two indicated groups as shown by the bar, where 
p<0.05 = *   
There are less KO transferred B cells present at day five compared to WT 
transferred B cells  Flow cytometry was performed on splenocytes. This was not performed on the WT>KO group. Gating analysis is summarised in figure 6A, and results in 6B. Transferred cells were identifiable from the eYFP, detectable in the FITC channel. WT transferred cells have increased significantly by day 5, where they are also significantly greater in frequency than KO transferred cells. Of these transferred cells at day 5, a greater frequency express the plasmablast/plasma cell marker CD138, although this was not significant. A similar frequency of the CD138- transferred cells were found to express the GC marker Fas. The greater number of WT transferred cells agrees with the quantification data above.   
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Figure 6: flow cytometry of splenocytes. eYFP +Naïve B cells from WT QM and cRel-/- (KO) QM mice 
were transferred into WT or KO hosts. Mice were then immunised with NP-Ficoll and spleens 
analysed at the indicated time points. Flow cytometry was performed on splenocytes and 
representative gating analysis is showing in A, where arrows to the right indicate gate analysis in the 
next FACS plot. Splenocytes were gated for lymphocytes, single cells then live cells (not shown). Live 
cells were then gated for transferred cells, which stained positive for eYFP. Transferred cells were 
gated for ability to bind NP (NP+) and from day 5, whether they were plasmablasts/plasma cells 
(CD138+) or not (CD138-). The non-plasmablast/plasma cell gate was then gated for GC B cells (Fas+). 
In B, data from flow cytometry is shown. Downwards arrows indicate quantification data from the 
gating analysis of part A. Data shows the individual mouse values. The black lines within each group 
represent the group median. Statistical analysis involved the Mann-Whitney test between the two 
indicated groups as shown by the bar, where p<0.05 = * and ns = non-significant. 
 
B cells that lack cRel have poor antibody production  Serum was obtained from sacrificed mice and analysed for NP-specific antibody as seen in figure 7. WT>WT NP-specific IgM levels are still low by day 2, but by day 5 high levels are seen. When ELISA is performed for detection of only NP specific IgMa, which allows detection of only the antibody produced by transferred cells, we again see high levels in WT>WT. NP-specific IgG is undetectable until day 5, at which point transferred WT cells are capable of producing some IgG1 in WT>WT. Small levels of high affinity IgG are also detectable in WT>WT mice by day 5.   
A        B 
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KO>WT mice also produce similar levels IgM by day 2. NP-specific IgM is slightly, but significantly lower in KO>WT mice by day 7. However, when we look at IgMa its apparent that the KO transferred cells give only barely detectable levels by day 5. This suggests the KO transferred cells give minimal contribution to the IgM response. KO>WT mice did not give a detectable NP-specific IgG response.  WT>KO mice gave similar antibody levels at day 5 to WT>WT mice. This included IgMa and IgGa produced only by the transferred cells. This suggests NP-specific WT cells in the KO environment are differentiating in absence of competition from the cRel deficient host cells.  
 
Figure 7: NP-specific antibody ELISA. Naïve B cells from WT QM and cRel-/- (KO) QM mice were 
transferred into WT or KO hosts. Mice were then immunised with NP-Ficoll. Mice were sacrificed and 
serum was taking at the indicated time points and ELISA performed for various antibody isotypes. 
Each data point represents a single individual mouse value. The black lines within each group 
represent the group median. Statistical analysis involved the Mann-Whitney test between the two 
indicated groups as shown by the bar, where p<0.05 = * and ns = non significant.  
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The absence of cRel from B cell or from environment does not effect IRF4 
transcription 
 IRF4 is upregulated in activated B cells and a high expression is required for plasma cell differentiation 29. Since cRel is implicated in IRF4 induction 33 and since IRF4 is high in plasma cells we expected that, giving the reduction in plasma cells in the KO>WT mouse groups, IRF4 will be reduced, by day 5 compared to WT.QM groups. For this experiment, an unimmunised control group was required to compare background IRF4 levels. For this, the day 0 WT cohort from the first experiment was used. Spleen sections were cut and cDNA prepared from whole sections. PCR was then performed for IRF4 transcripts as shown in figure 8.  In both groups Irf4 expression from the whole spleen has increased compared to our background control by 2 hours, as seen in figure. Neither the WT>WT or KO>WT groups at 2 hours were significantly greater than background (not shown). However, taking both groups into a single 2 hour group did give a significant increase compared to background. Irf4 transcripts then decrease to background levels at day 2 in both groups. This agrees with previous data from the Toellner lab (Laura George, unpublished data). Surprisingly, Irf4 did not increase to day 5 in any group, despite the high numbers of plasma cells in the WT>WT and WT>KO groups.   
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Figure 8: splenic irf4 transcripts levels compared to housekeeping gene transcripts (β2m). Naïve B 
cells from WT QM and cRel-/- (KO) QM mice were transferred into WT or KO hosts. Mice were then 
immunised with NP-Ficoll and sacrificed at the indicated time points. A non-immunised WT group 
was also included as a background control. cDNA was prepared from spleen sections. PCR was 
performed for detection of irf4 and β2m transcripts. Each data point shows individual values from 
single mice. The black lines within each group represent the group median. Statistical analysis 
involved the Mann-Whitney test between the non immunised group, and the two 2 hour groups as a 
whole, as shown by the bar, where p<0.05 = *  
Mice receiving WT or KO B cells have a similar ability to initiate CSR  The appearance of immunoglobulin heavy chain germline transcripts (IgH switch transcripts) correlates with induction of CSR. The low titres of IgG seen in KO>WT mice could be due to lack of transcription through the Ig heavy chain switch regions. PCR of whole spleen sections was performed as before, with detection of the IgG1 switch transcript; IgG3 switch transcript; and Recombined IgM – IgG3 heavy chain transcript which indicates successful class switch recombination to IgG3 as shown in figure 9.  The IgG1 switch transcript is required for switching to IgG1. By day 2, the WT>WT group produce high levels of this transcript, significantly higher than 
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background, yet this does not increase to day 5. The KO>WT group is still at background by day 2, although one mouse gave a high level. By day 5, the KO>WT group has largely caught up to the WT>WT, although the median is slightly lower.   The IgG3 switch transcript is required for switching to IgG3. Surprisingly, the non-immunised control group has a very high transcript level. All immunised groups at each time point show great variation, but in terms of the median, they increase from the 2 hour time point and are all similar levels by day 2 and 5.  The recombined IgG3 heavy chain transcript shows the level of IgG3 that is being transcribed. Similarly, the non-immunised control is higher than expected. At 2 hours and 2 days, the WT>WT groups are slightly higher than the KO>WT groups.  Both groups have increased by day 5 above background level and to a similar level. The same mouse that had low day 5 IgG3 switch transcripts from the KO>WT group was well below background IgG3 heavy chain transcripts at day 5. The WT>KO control group is also slightly lower. Together, results suggest the lack of IgG detection by day 5 in KO>WT mice is not due to an inability produce switch transcripts across the whole spleen.  
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Figure 9: splenic switch and recombined heavy chain transcript levels compared to housekeeping 
gene transcripts (β2m). Naïve B cells from WT QM and cRel-/- (KO) QM mice were transferred into 
WT or KO hosts. Mice were then immunised with NP-Ficoll and sacrificed at the indicated time 
points. A non-immunised WT group was also included as a background control. cDNA was prepared 
from spleen sections. PCR was performed for detection of igg1 switch transcript; igg3 switch 
transcript; recombined igg3 heavy chain transcript; and β2m transcripts. Each data point shows 
individual values from single mice. The black lines within each group represent the group median. 
Statistical analysis involved the Mann-Whitney test between the two indicated groups as shown by 
the bar, where p<0.05 = * and ns = non significant. 
Splenic AID transcript levels are similar between WT and KO groups  AID is a key factor of CSR and is regulated by IRF4, we therefore investigated its induction throughout the immune response. PCR was performed as before with detection of aid transcripts. Previous studies have found aid transcript expression in B blasts from the follicle-T zone border from 2 days after NP-Ficoll immunisation (Marshall 2011). Coinciding with the induction of CSR, Aid transcripts are above background 2 days after immunisation in both the WT>WT and KO>WT groups as shown in figure 10. Although KO>WT level is slightly lower than WT>WT, this difference was not significant. Similar levels of 
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transcript are also found at day 5. Since AID is not expressed in plasmablasts or plasma cells 6,	  this	  probably	  reflects	  AID	  expressed	  in	  GC’s.    
 
Figure 10: splenic aid transcript levels compared to housekeeping gene transcripts (β2m). Naïve B 
cells from WT QM and cRel-/- (KO) QM mice were transferred into WT or KO hosts. Mice were then 
immunised with NP-Ficoll and sacrificed at the indicated time points. A non-immunised WT group 
was also included as a background control. cDNA was prepared from spleen sections. PCR was 
performed for detection of aid and B2m transcripts. Each data point shows individual values from 
single mice. The black lines within each group represent the group median. Statistical analysis 
involved the Mann-Whitney test between the two indicated groups as shown by the bar, where 
p<0.05 = * and ns = non significant. 
The absence of cRel does not affect the ability of plasma cells to switch to IgG  The previous PCR experiments show there is little defect at a global level in Irf4 transcripts, switch transcripts and Aid transcripts. Since ELISA data showed transferred cells were poor producers of IgG, these cells may not have actually switched to IgG. In order to investigate the ability the specific transferred cells to switch from IgM to IgG at a cellular level, splenic sections from day 5 only were placed onto slides as before. Slides were then fluorescently stained for the QM IgH idiotype, IgD to indicate follicular areas, and IgM and IgG to analyse class switching. The percentage of transferred plasma cells that costained for IgG were 
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then quantified and presented in figure 11. Typical images of foci are shown in figure 12.   Despite the variation in the WT.QM>WT group, there is no difference in the ability of Idiotype cells to switch to IgG. Of course, there are much less transferred cells/plasma cells present at day 5 in the KO.QM group (figure 6B and 13). Only small numbers of idiotype cells are involved in foci of KO>WT spleens compared to the majority seen in WT>WT and WT>KO (figures 12 and 13).      
 
Figure 11: percentage of  IgG+ transferred cells. Naïve B cells from WT QM and cRel-/- (KO) QM mice 
were transferred into WT or KO hosts. Mice were then immunised with NP-Ficoll and at day 5 
spleens were removed for analysis. Splenic sections were cut onto slides, which were fluorescently 
stained for transferred cells, IgM and IgG. The percentage of transferred cells which costained for 
IgG were quantified. 
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Figure 12: Fluorescent images and merges from spleen sections.  Naïve B cells from WT QM and cRel-
/- (KO) QM mice were transferred into WT hosts  (WT>WT), (KO>WT). Mice were then immunised 
with NP-Ficoll and 5 days later, spleens were sectioned and fluorescent staining was performed. 
Each column shows a representative section from a WT>WT (left), KO>WT (middle) mouse and a 
negative control section (right). The negative control received no primary antibody. Staining used 
was anti-idiotype (blue) to show transferred cells; anti-IgG (red); anti-IgM (green) and anti-IgD 
(grey). Each column shows a single colour stain for idiotype, IgG and IgM as indicated. The last row 
shows the merge of these single stains all together, with IgD. Arrows indicate a particular idiotype 
plasma cells that also expresses IgG as well as IgM. These cells show up as white staining in the 
merge.
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Figure 13: Tilescans of typical whole spleen sections. Naïve B cells from WT QM and cRel-/- (KO) QM mice were transferred into WT or KO hosts. 
Mice were then immunised with NP-Ficoll and at day 5 spleens were removed for analysis. Splenic sections were cut onto slides, which were 
fluorescently stained for transferred cells with idiotype (blue), IgG (red) and IgD (grey). WT>WT spleen is on the left; KO>WT in middle; WT>KO on 
right.  Costaining of idiotype and IgG is seen as purple staining. Tilescans were made from individual images at 10x and pieced together. Scale is 
representative for all figures 
WT>WT         KO>WT            WT>KO 
Idiotype 
IgG 
IgD 
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Discussion   Immunisation of both WT C57/BL6 mice and C57/BL6 mice transferred with WT.QM B cells resulted in a strong extrafollicular immune response with high numbers of splenic red pulp NP-specific plasma cells. These plasma cells peaked at day 5 after immunisation. From the first experiment, we see the numbers stay constant to day 7. This is consistent with previous studies which found NP-Ficoll immunisation of C57BL6 mice resulted in foci first appearing at day 3 and peaking at day 5 before decreasing in week two after immunisation 46.   We found that in cRel KO mice, NP-specific plasma cells do not increase above background until after day 5. This defect was found to be B cell intrinsic, since cRel absence in only B cells still resulted in small plasma cell numbers compared to WT>WT mice, whereas a B cell extrinsic absence had no effect, at least at day 5. Flow cytometry data also showed significantly less transferred cells by day 5 in KO>WT mice. This difference is transferred cell/plasma cell numbers likely reflects a decreased proliferation and increased apoptosis in the absence of intrinsic cRel.   cRel KO B cells also show increased apoptosis to mitogenic stimuli, including BCR ligation 474849. Members of the Bcl2 pro-survival gene family, BclXL and A1 have been found to be cRel target genes in B cells 50. Transgenic expression of either of these in cRel KO B cells can provide partial protection from apoptosis upon BCR ligation 50,51. It is therefore likely that the strong BCR crosslinkage 
 36 
caused by NP results in a high level of apoptosis in cRel KO B cells. Hence, many of the responding NP-specific cells do not survive, so never contribute to plasma cell and antibody production.   Previous studies describe how cRel KO B Cells show poor proliferation 4847 49 and its been shown these B cells fail to progress from the G1 to S phase of the cell cycle 52. The cRel target gene E2F3a is important in transition to the S phase 53. E2F3a activity allows induction of cyclin-E. Cyclin-CDK complexes are formed upon BCR ligation and allow hyperphosphorylation and inactivation of Rb. Rb can then no longer bind and repress E2F proteins, allowing them to facilitate cell cycle progression. Therefore, any responding cRel KO B cells that do survive are likely to be unable to proliferate and contribute to high plasma cell numbers. Future study could confirm in vivo proliferation defects through CFSE labelling with flow cytometry, or BrdU staining with immunohistology.  Despite this, NP-specific plasma cells increased between day 5 and 7 in some cRel KO mice, with a group median increase of around 6 fold. cRel mRNA has been found to be downregulated in plasma cells compared to mature B cells 54,55. It is therefore possible that responding NP-specific cells that do survive and make it to the plasmablast stage, will be less affected by the cRel deficiency and capable of some clonal proliferation before terminal differentiation to plasma cells.  Even before immunisation, NP-specific IgM was detectable at low titres, in some mice from both the WT and KO groups. This will most likely be natural antibody, 
 37 
produced by B1 B cells and MZ B cells. The higher titres detected from day 5 will reflect antibody produced during the NP-specific immune response.  NP-specific IgM peaks at day 7, which is similar to previous studies which found significant titres of NP-specific IgM by day 5, peaking at day 7 and remaining high thereafter 
46.   IgG3 was reported to be the major switched antibody produced, along with high some IgG1 during an NP-Ficoll response 46. Likewise, during the WT response, we found IgG3 to give the highest IgG titre and significant titres of IgG1 were also detected. The absence of cRel results in poor NP-specific antibody detection. From the first experiment, we see that KO mice have reduced antibody production of IgM and IgG. KO antibody production does increase however at day 7, and this correlates with the increase in NP-specific plasma cells.  The adoptive transfer experiment shows that, despite high IgM titres, KO B cells do not contribute much to IgM production. Again, this likely reflects the very low numbers of KO transferred cells/plasma cells by day 5. Endogenous cells must then be responsible for this IgM, but surprisingly, even endogenous cells fail to produce much detectable IgG. The high levels of antibody of QM idiotype from the QM cRel WT cells suggest endogenous cells may not be the major antibody producers in these mice. The high frequency of NP-specific transferred cells may be able to outcompete endogenous cells for an accessory cell, such as CD11+ DC’s,	  for class switching signals. Thus, low frequencies of NP-specific endogenous cells in KO>WT mice may be initially outcompeted and possibly miss out on switching signals. However the KO>WT tilescan did show endogenous cells have switched 
 38 
to IgG. A lot of these foci lacked idiotype	  cells,	  so	  it’s possible that they were not NP-specific.    Previous studies have described serum levels of IgM, IgG1, IgG2a, IgG2b and IgG3 to be reduced in cRel KO mice 48. IgG3 was shown to be marginally reduced at day 7 post NP-LPS immunisation in cRel knock out mice, though other isotypes were not tested, IgG1 was largely reduced after TD NP-KLH immunisation 48. However, this study did not attribute whether this was due to an actual defect in antibody production/switching or simply reduced plasma cell numbers.  It has been described in vitro that cRel KO B cells fail to switch to IgG3, IgG1 or IgE in response to the appropriate stimuli 5643. This correlated with lack of induction of IgG1 and IgG3 switch transcripts. A cRel binding site has been described in the I promoter of the IgG1 switch transcript 57. cRel has also been 
proposed	  to	  bind	  to	  the	  3’IgH	  enhancer	  downstream	  of	  the	  CH locus, another way cRel could regulate CSR 42. On top of this, cRel KO B cells fail to switch to IgE in 
vitro despite normal induction of the E switch transcript 56, suggesting other roles for cRel in CSR and antibody production.  We investigated the ability for CSR at a global level from the spleens from the second experiment. During the NP-Ficoll response, IgG3 switch transcripts increase above background within 24 hours 46. Likewise, we found in WT>WT mice, IgG1 and IgG3 switch transcripts are expressed to high levels by day 2. The median level of these transcripts did not increase by day 5, despite the high numbers of plasma cells within the extrafollicular foci at day 5.  
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 It was also noted that the non-immunised mouse group did have rather high levels of the IgG3 switch transcript especially. We think its unlikely this group represent the background Cγ3 switch transcripts which would have been found in the immunised mouse groups before immunisation, since IgG3 is the dominant antibody response yet switch transcripts were never above background and have apparently decreased significantly within two hours. These mice may have had a background immune response resulting in high IgG3 (not specific to NP). This control group was not part of the original experimental set up, and therefore there may have been a higher background response in this cohort due to a non-related infection.   IgG1 switch transcripts were reduced at day 2 in most KO>WT mice compared to WT>WT mice, but by day 5, transcripts were equivalent, as were IgG3 switch transcripts. The ability to complete CSR and transcribe a recombined IgG3 antibody was also equivalent in the KO>WT and WT>WT groups by day 5. A similar relationship was found with Aid transcription. Although this did not show that our cRel KO B cells are capable of CSR, it shows that at a global level, B cells in the spleen should be capable of switching and producing a detectable IgG response.   We did however investigate the ability of the transferred cells to switch to IgG expression at day 5 by fluorescent staining with costaining for idiotype and IgG. Perhaps surprisingly, there was no difference in the proportion of transferred cells that were now expressing IgG.  Although there were a lot less transferred 
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cells that became plasma cells, similar proportions of transferred cells had switched to IgG in both the WT>WT and KO>WT as well as the WT>KO mice. This would also agree with the earlier possibility that transferred cells may outcompete endogenous cells for switching signals. While the subclass of IgG was not determined, this result taking together with the PCR data does suggest that the absence of cRel does not affect CSR and IgG expression during an NP-Ficoll response.  Splenic Irf4 transcripts increased within the first 2 hours. It has been shown that MITF negatively regulates IRF4 in naïve B cells 31. After in vitro B cell activation, 
Mitf transcripts decrease while Irf4 increases. This lab has previously found Irf4 transcripts to increase in the first 4 hours after immunisation before falling to low levels again (Laura George, personal communication).   Giving that high IRF4 levels are thought to be required for plasma cell differentiation 29, we expected to find high irf4 levels by day 5. The lack of this may be due to Irf4 transcripts being transiently expressed at high levels before day 5, and this phase of initiation of plasma cell differentiation may have been missed. It is also possible that PCR of the whole spleen is not sensitive enough to pick up small changes in B cell Irf4 expression, particularly if IRF4- GC cells are present by day 5. The data is compatible with the absence of cRel allowing low level IRF4 expression required for AID induction and CSR, but not the high levels of IRF4 required for plasma cell differentiation 29.   
 41 
Ideally, PCR should be performed on sorted cells, such as the transferred cells. This would allow an accurate and sensitive analysis of transcription in the transferred B cells without the influence of other cells. For example, Aid transcripts should not be seen by day 5 in transferred cells that have become plasma cells, but Aid is also expressed in GC B cells, and is under different regulation. This could explain why we still see Aid transcripts at this time point. Antigen-specific B cell populations have been FACS sorted during this study, and future analysis should focus on gene expression in isolated cells.  Despite what was found in previous studies, we found cRel KO to have no effect on IRF4 induction or CSR. Since these previous studies involved in vitro work, it is possible that different signals and the local environment can overcome potential defects in IRF4 and CSR.  However, cRel deficiency leads to a reduction in the amount of NP-specific plasma cells found, and subsequently, the level of antibody detected was much lower. As discussed above, it is likely that the RT-PCR from whole tissue sections is not sensitive enough and future studies on isolated cells may be more accurate. We also hypothesise that a high level expression of IRF4 (present in WT cells, and possibly absent in cRel KO cells), was missed because an earlier time point should have be chosen for the analysis of high level IRF4 expression triggering plasma cell differentiation, and future studies could address this. 
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Appendix   
Table 1: Antibody for flow cytometry 
Antibody 
specificity 
Conjugation Dilution Company B220 PE-Cy5.5 1/300 BD pharmingen NP PE 1/30,000 Gift from Prof Peter Lane  Fas PE-Cy7 1/100 BD pharmingen CD138 APC 1/100 BD pharmingen  
 
Table 2: Unconjugated immunohistochemistry antibody 
Specificity Dilution Company Rat anti-mouse CD3 1/1000 AbD serotec Sheep anti-mouse IgD 1/1000 Abcam Sheep anti-NP 1/3000 In house Rat anti-mouse IgD 1/1000 BD pharm Rat anti-idiotype 1/100 Gift from Dr Imanish-Kari  
Table 3: Conjugated immunohistochemistry secondary antibody 
Specificity  Conjugation Dilution Company Rabbit anti-rat biotin 1/600 Dako Donkey anti-sheep peroxide 1/100 The Binding Site Donkey anti-sheep biotin 1/100 The Binding Site Rabbit anti-rat peroxide 1/80 Dako    
Table 4: Buffers and substrates for immunohistology Tris pH 7.6 1.5L Physiological NaCl 1.5L 0.1M Hcl 1.0L 0.2M Tris Tris pH 9.2 As for pH 7.6 but made to pH 9.2 Peroxidase substrate One DAB  tablet (sigma) dissolved in 15ml of Tris pH 7.6. 10ml was then filtered with the addition of one drop of hydrogen peroxide Alkaline phosphate substrate 8mg of Levamisole (Sigma) is dissolved in 10ml of Tris pH 9.2. Naphtol AS-MX phosphate was dissolved in 370μl of dimethyl formamide (sigma). This was added to the Levamisole solution, before 10mg of fast blue BB salt (Sigma) was added and the final solution was filtered. 
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Table 5: Fluorescent antibody staining 
Specificity conjugation Dilution Company Rat anti-mouse IgG - 1/200 AbD serotec Donkey anti-rat Cy3 1/200 Milipore Anti-IgD PB 1/50 eBiosciences  Rat anti-idiotype Cy5 1/100 Gift from Dr Imanish-Kari Goat anti-mouse IgM FITC 1/100 Southern Biotech    
Table 6: PCR reverse transcription mix 
Reverse transcription 
mix 
Volumes required per 
sample 
Company 
 5x first strand buffer 12μl Invitrogen 0.1M DTT 6μl Invitrogen 
10mM	  dNTP’s 3μl Invitrogen MMLV reverse transcriptase 3μl Invitrogen RNasin RNase inhibitor 1.5μl Promega RNase free water 1.5μl Quigon  
 
Table 8: Primers and probes required for real time PCR 
Name of target sequence Nucleotide sequence 
β2-Microglulin  Forward primer CATACGCCTGCAGAGTTAAGCA 
Reverse primer ATCACATGTCTCGATCCCAGTAGA 
TaqMan probe CAGTATGGCCGAGCCCAAGACCG 
IRF4 Forward primer GGAGGACGCTGCCCTCTT 
Reverse primer TCTGGCTTGTCGATCCCTTCT  
TaqMan probe AGGCTTGGGCATTGTTTAAAGGCAAGTTC  
IgG1 switch 
transcript  
Forward primer CGAGAAGCCTGAGGAATGTGT 
Reverse primer GGAGTTAGTTTGGGCAGCAGAT 
TaqMan probe TGGTTCTCTCAACCTGTAGTCCATGCCA 
recombined IgG3 
heavy chain 
transcript  
Forward primer TCTGGACCTCTCCGAAACCA 
Reverse primer ACCGAGGATCCAGATGTGTCA 
TaqMan probe CTGTCTATCCCTTGGTCCCTGGCTGC 
IgG3 heavy chain 
germline transcript 
Forward primer GACCAAATTCGCTGAGTCATCA 
Reverse primer ACCGAGGATCCAGATGTGTCA 
TaqMan probe CTGTCTATCCCTTGGTCCCTGGCTGC 
AID Forward primer GTCCGGCTAACCAGACAACTTC 
Reverse primer GCTTTCAAAATCCCAACATACGA 
TaqMan probe TGCATCTCGCAAGTCATCGACTTCGT 
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Table 8: Experiment 2 ELISA serum dilutions and antibodies 
ELISA 
type 
Antibody 
detection 
Conjugation Antibody 
company 
Serum and 
negative 
standard 
dilution 
Positive 
standard 
serum 
dilution NP15 IgM AP Southern Biotech 1/30 1/50 NP15 Total IgG AP Southern Biotech 1/10 1/100 NP15 IgG1 AP Southern Biotech 1/10 1/100 NP15 IgG2a AP Southern Biotech 1/10 1/20 NP15 IgG3 AP Southern Biotech 1/10 1/20   
Table 9: Experiment 2 ELISA serum dilutions and antibodies 
ELISA 
type 
Antibody 
detection 
Conjugation Antibody 
company 
Serum and 
negative 
standard 
dilution 
Positive 
standard 
serum 
dilution NP15 IgM AP Southern Biotech 1/20 1/30 NP15 Total IgG AP Southern Biotech 1/10 1/200 NP15 IgG1a - Biolegend 1/10 1/10 NP15 IgMa - Biolegend 1/10 1/10 NP2 IgG AP Southern Biotech 1/10 1/50  
